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Abstract
Suppose one has data from one or more completed vaccine efficacy
trials and wishes to estimate the efficacy in a new setting. Often logisti-
cal or ethical considerations make running another efficacy trial impos-
sible. Fortunately, if there is a biomarker that is the primary modifier
of efficacy, then the biomarker-conditional efficacy may be identical in
the completed trials and the new setting, or at least informative enough
to meaningfully bound this quantity. Given a sample of this biomarker
from the new population, we might hope we can bridge the results of
the completed trials to estimate the vaccine efficacy in this new pop-
ulation. Unfortunately, even knowing the true conditional efficacy in
the new population fails to identify the marginal efficacy due to the un-
known conditional unvaccinated risk. We define a curve that partially
identifies (lower bounds) the marginal efficacy in the new population as
a function of the population’s marginal unvaccinated risk, under the as-
sumption that one can identify bounds on the conditional unvaccinated
risk in the new population. Interpreting the curve only requires iden-
tifying plausible regions of the marginal unvaccinated risk in the new
population. We present a nonparametric estimator of this curve and
develop valid lower confidence bounds that concentrate at a parametric
rate. We use vaccine terminology throughout, but the results apply to
general binary interventions and bounded outcomes.
Keywords: bridging; external validity; generalizability; partial identification;
transportability; vaccine efficacy
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1 Introduction
Randomized clinical trials are the gold standard for evaluating the effect of
a new intervention in a population. However, it is not always possible or
appropriate to conduct a Phase 3 efficacy trial. In these cases, it is desir-
able to “bridge” results from earlier trials to a new setting that may differ
in population, treatment version, or exposure levels. Being able to extrapo-
late efficacy signals to a new population is a special case of generalizability
or external validity (Cole and Stuart, 2010), and is often referred to as trans-
portability (Bareinboim and Pearl, 2012, 2013; Pearl and Bareinboim, 2014).
Following the clinical trials literature, we will instead refer to this extrapola-
tion as “bridging” (Gilbert and Hudgens, 2008; Gilbert et al., 2011; Fleming
and Powers, 2012).
There have been several recent trials establishing the efficacy of the CYD-
TDV vaccine in children. In particular, CYD14 found 56% per-protocol effi-
cacy of the vaccine in Asian children aged 2-14 years (Capeding et al., 2014),
CYD15 found 61% per-protocol efficacy the same vaccine in Latin American
children aged 9-16 years (Villar et al., 2015), and CYD23 found 30% per-
protocol efficacy in Thai children aged 4-11 years (Sabchareon et al., 2012).
All trials featured a 2:1 vaccine:placebo randomization scheme, with respective
sample sizes of approximately 10,000, 21,000, and 4,000 and respective viro-
logically confirmed dengue event counts of 250, 397, and 134. In each trial,
efficacy was shown to increase with age and prior exposure to dengue (Caped-
ing et al., 2014; Villar et al., 2015; Sabchareon et al., 2012). While several
countries have licensed the CYD-TDV vaccine for individuals from 9–45 or
9–60 (WHO, 2016), many countries have still not licensed this vaccine due to
debates over the appropriate ages of indication. Nonetheless, the high esti-
mated efficacy in the existing trials may make further Phase 3 trials unethical.
There is thus compelling motivation to bridge the results of the earlier efficacy
trials completed in children to the adult population.
The focus of most existing work on bridging is on bridging the results
from a single efficacy trial to a new population. Unsurprisingly, some assump-
tions must be made to bridge between the two studies. The primary standard
assumption is that (i) the two populations have equivalent outcome regres-
sions, i.e. that the mean outcome within each treatment/covariate/immune
response biomarkers stratum is constant, and (ii) that the support of the
treatment/covariate/immune response biomarker distribution in the popula-
tion to which the researchers wish to bridge is contained in the corresponding
support in the population in which the trial was completed (Bareinboim and
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Pearl, 2012, 2013; Pearl and Bareinboim, 2014). Recently, an efficient, double
robust estimator was established when these assumptions hold (Rudolph and
van der Laan, 2016). There has also been some work on establishing trans-
portation formulas when there are multiple settings in which full observations
are observed in more than one setting, which in our setting means that there
is more than one completed efficacy trial (Lee and Honavar, 2013; Bareinboim
and Pearl, 2014).
Assumption (i) is often not plausible in the infectious disease setting unless
one adjusts for the level of pathogen exposure, but in most efficacy trials there
is only coarse exposure data (e.g., age in dengue trials). Furthermore, adjust-
ing for level of pathogen exposure can violate Condition (ii) in some scenarios.
To overcome this problem, Gilbert and Huang (2016) posited a bridging as-
sumption on the ratio scale, arguing that the vaccine versus placebo risk ratios
in the two populations should be approximately equal within each covariate-
specific principal stratum because this ratio reflects the vaccine’s effect on
biological susceptibility to pathogen infection or disease. Because knowing the
risk ratio does not uniquely determine the outcome regression, there remains
an undetermined degree of freedom. One possibility is to estimate the out-
come regression among unvaccinated participants in the new population using
epidemiological data (Gilbert and Huang, 2016).
There is often severe underreporting of infection or disease incidence in the
available epidemiologic surveillance data. For example, recent studies com-
paring active and passive surveillance (by national surveillance programs) of
dengue incidence have seen up to 19-fold underreporting in the passive surveil-
lance (Nealon et al., 2016; Sarti et al., 2016). Though one could attempt to
account for the underreporting by specifying an inflation factor for the passive
surveillance data, there will likely be uncertainty around what exactly this
inflation factor should be. For this reason, in this work we focus on a less rigid
approach to account for the unknown unvaccinated risk allocation. In partic-
ular, we derive the worst-case allocation under constraints that we will impose
in the next section. These constraints can be estimated via epidemiologic data
or existing trial data. This then yields the lower bound on the vaccine efficacy
in the new population that we wish to estimate using double robust methods
(e.g., Robins and Rotnitzky, 1995; van der Laan and Robins, 2003; van der
Laan and Rose, 2011). Identifying a parameter that provides a bound on an
unidentifiable parameter is often referred to as partial identification (Manski,
2003), and these identification problems have received considerable attention
over the last several decades (e.g., Manski, 1990; Horowitz and Manski, 2000;
MacLehose et al., 2005). Because we are specifically focused on bridging a
parameter from one or several populations to a new setting, we refer to this
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exercise as partial bridging, though really our objective is a special case of
partial identification.
Organization of article. Section 2 describes the observed data and presents
a lower bound on the vaccine efficacy in the new population. Section 3 derives
a first-order approximation to the lower bound of inference that will play a key
role in our estimation scheme. Section 4 describes our estimation scheme, with
Section 4.1 focusing on the case where the conditional vaccine efficacy surface
is not known to be constant across completed efficacy trials, and Section 4.2
describing how to improve the precision of the lower confidence bound when
the conditional efficacy surface is known to be the same across the completed
efficacy trials. Section 5 presents a simulation study. Section 6 concludes with
some brief remarks.
All of our proofs can be found in Appendix B. Appendix A presents tech-
nical regularity conditions used to establish the validity of our estimator. Ap-
pendix E extends our results to two-phase sampling designs and monotonic
vaccine efficacy curves. Appendix F presents simulation results under a two-
phase sampling design.
2 Problem setup
2.1 Notation and bridging assumptions
Before presenting our problem, we introduce a few basic pieces of notation.
For functions f and g mapping from some space X to another space Z, we
write f ≡ g to denote equality of f(x) and g(x) for all x. We also write f ≡ 0
to denote that f(x) = 0 for all x. We use “,” to denote a definition, e.g.
f(x) , x denotes the identity map. When we want to emphasize that f is a
function, we refer to f as w 7→ f(w). As is standard in the empirical process
literature, we let Pf denote the expectation of f(X) when X is drawn from
the distribution P (e.g., van der Vaart and Wellner, 1996).
Consider the data structure (W,A, Y ), where W is a (possibly multivari-
ate) baseline (pre-randomization) biomarker, A is a vaccination indicator, and
Y is the outcome of interest that occurs subsequent to vaccination. While
all of the results in this work hold for general bounded Y , we focus on the
case that Y is an indicator of infection or disease, since this is our primary
case of interest. To avoid introducing additional burdensome notation, we as-
sume that the outcome Y is observed on all individuals, though we note in
the Discussion (Section 6) that the extension to right-censored outcomes is
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straightforward. Suppose that we have already observed trials in Populations
1, . . . , S. Each trial s consists of ns independent and identically distributed
(i.i.d.) observations Os[1], . . . , Os[ns] of the structure Os , (W,A, Y ) ∼ P 0s ,
where P 0s is known to belong to the modelMs that at most places restrictions
on the conditional distribution of A given W and such that each P ′s ∈ Ms
satisfies δ < mina∈{0,1} P ′s(A = a|W ) with P 0s probability one. Thus, we as-
sume that all efficacy trials tested the same vaccine versus control/placebo
and collected the same W and Y following the same protocol. While it is
not essential that the data from each P 0s be drawn from a randomized trial,
we refer to data from P 0s as data from “trial s” because that is our primary
application of interest.
From each trial s we have an estimate of the vaccine efficacy, given by
1− E0s[E0s[Y |A=1,W ]]E0s[E0s[Y |A=0,W ]] , where E
0
s is the expectation operator under P
0
s . If A is inde-
pendent of W , then this reduces to estimating a covariate-unadjusted vaccine
efficacy. Our objective is to estimate the vaccine efficacy in a new population
?. Were we to run a trial in this population, we would observe i.i.d. copies of
(W,A, Y ) ∼ P 0,F? , and we could then estimate the vaccine efficacy
Ψ(P 0,F? ) , 1−
E0,F?
[
E0,F? [Y |A = 1,W ]
]
E0,F?
[
E0,F? [Y |A = 0,W ]
] ,
where we use E0,F? to denote the expectation operator under P 0,F? . In practice
we do not observe a trial from population ?, but rather a size n? i.i.d. sample
of observations O?[1], . . . , O?[n?] containing only O? , W ∼ P 0? , where P 0?
is the marginal distribution of W under P 0,F? . We denote the nonparametric
model for P 0? by M?. Our objective is to obtain a lower bound on Ψ(P 0,F? )
based on assumptions of how P 0,F? is related to the distributions P1, . . . , PS
from the completed trials. We refer to these assumptions as bridging assump-
tions. Because we only make assumptions that are biologically justifiable in
a wide variety of examples, we are often unable to identify Ψ(P 0,F? ) with any
parameter mapping of the collection of distributions P0 , (P 0? , P 01 , . . . , P 0S).
We are, however, able to identify a parameter mapping that lower bounds this
quantity under our bridging assumptions. Obtaining such bounds is the objec-
tive of the partial identification literature (Manski, 2003). A consequence of
our partial bridging is that our estimator of the lower bound does not generally
converge to Ψ(P 0,F? ) even as n?, n1, . . . , nS all grow to infinity.
Before proceeding, we introduce some notation. We let P0 , (P 0? , P 01 , . . . , P 0S)
and n , n? +
∑S
s=1 ns. We treat each of the sample sizes ns as deterministic.
We let M , M? ×
∏S
s=1Ms denote the model for P0. For members P ′s of
the general collection P ′ , {P ′?, P ′1, . . . , P ′S}, we let E′s denote the expectation
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under P ′. We also let S = {?, 1, . . . , S}. For Trials s = 1, . . . , S, we define the
conditional vaccine efficacy as follows
VE0s(w) , 1−
E0s[Y |A = 1, w]
E0s[Y |A = 0, w]
.
We define the unidentifiable conditional vaccine efficacy in population ? sim-
ilarly, with the expectations under P 0s above replaced by expectations under
P 0,F? .
We now define a lower bound on the curve w 7→ VE0,F? (w). This lower
bound is defined using data from the completed trials s = 1, . . . , S, and
also possibly vaccinated/unvaccinated conditional risks from a user-defined
pseudo-population, which we denote s = 0. This pseudo-population can
be used to make our vaccine efficacy curve assumption more plausible. Let
vs : W → [0, 1], s = 0, 1, . . . , S, be a collection of functions satisfying the
convexity constraint
∑S
s=0 vs(w) = 1 for all w. Let d : A ×W → [0, 1] be a
function for which d(0, w) and d(1, w) respectively represent the unvaccinated
and vaccinated risk in the user-defined pseudo-trial. Define
VE0−(w) , 1−
v0(w)d(1, w) +
∑S
s=1 vs(w)Es[Y |A = 1, w]
v0(w)d(0, w) +
∑S
s=1 vs(w)Es[Y |A = 0, w]
.
For each w, the above expression gives weight vs(w) for the pseudo-trial s = 0
and each completed trial s = 1, . . . , S. That is, vs(w) indicates the hypotheti-
cal size of the stratum of w in trial s relative to the stratum of w in the other
trials and the pseudo-trial. If v0 ≡ 0, then the pseudo-trial gets zero weight,
whereas if v0(w) is large for many w, then the vaccinated and unvaccinated
risks d(1, w) and d(0, w) in the pseudo-trial play a major role in determining
w 7→ VE0−(w). Our first bridging assumption states that w 7→ VE0−(w) lower
bounds w 7→ VE0,F? (w).
B1) P 0? {VE0,F? (W ) ≥ VE0−(W )} = 1.
If VE0,F? ≡ VE01 ≡ . . . ≡ VE0S, then the stronger result P 0? {VE0,F? (W ) =
VE0−(W )} = 1 holds for any w 7→ VE0−(w) for which the pseudo-trial is given
zero weight, i.e. any v0, v1, . . . , vS satisfying v0 ≡ 0. We give a brief derivation
of this result in Section 4.2.
While the above conditions are helpful for bridging the marginal vaccine
efficacy from the completed trials to population ?, they do not allow one to
uniquely identify this marginal vaccine efficacy, even when the conditional
efficacy is point identifiable in the sense that P 0? {VE0,F? (W ) = VE0−(W )} = 1.
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In particular, we still need to understand the behavior of the conditional risk
among unvaccinated individuals in population ?. While getting a reasonable
estimate of this baseline risk may be difficult in practice, experts may be able
to give bounds on how small or large this risk may be. A flexible way of
communicating this expert knowledge is as follows. Let u0,u1, . . . ,uS be an
expert-specified set of functions mapping from W to R. Define the upper
bound υ0 , Υ(P0) on the unvaccinated risk pointwise by
υ0(w) , u0(w) +
S∑
s=1
us(w)E0s[Y |A = 0, w].
For the lower bound, let `0, `1, . . . , `S be an expert-specified set of functions
mapping from W to R. The lower bound λ0 , ΛP0 on the unvaccinated risk
is defined pointwise by
λ0(w) , `0(w) +
S∑
s=1
`s(w)E0s[Y |A = 0, w],
where for each w we require that λ0(w) ≤ υ0(w). We assume throughout that
υ0(w)− λ0(w) is uniformly bounded below by some δ > 0. Forcing δ > 0 will
not prove to be restrictive because Υ only needs to serve as an upper bound
for the conditional baseline risk (known to fall in the closed unit interval).
Having δ > 0 ensures that point identification of the vaccine efficacy Ψ(P 0,F? )
is impossible when the vaccine efficacy curve is nonconstant because we cannot
identify the baseline risk in population ?, i.e. w 7→ E0,F? [Y |A = 0, w].
The baseline risk assumption can be written as follows.
B2) λ0(W ) ≤ E0,F? [Y |A = 0,W ] ≤ υ0(W ) with P 0? probability one.
Our next bridging assumption essentially states that the support of population
? must be contained in the support of the completed trials, though, as we
explain below, is slightly more general than this stated condition.
B3) For each s = 1, . . . , S and each event E on W , P 0s (E) = 0 implies that
E0?[max{`s(W ),us(W ), vs(W )}1E] = 0.
The above is weaker than assuming that the marginal distribution of W under
P 0s dominates P
0
? for each s = 1, . . . , S since `s(W ), us(W ), and vs(W ) may
be selected to be 0 for populations where there is no support.
We also assume that w 7→ VE0−(w) satisfies a boundedness condition.
B4) w 7→ VE0−(w) is uniformly bounded on the support of W .
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The above ensures that integrals involving w 7→ VE0−(w) make sense – while
it could be replaced by a moment condition, the boundedness assumptions
simplifies our proofs and seems to give up little since it is rare that VE0−(w)
can be arbitrarily close to −∞.
2.2 Partial bridging formula
We now present lower bounds on the vaccine efficacy Ψ(P 0,F? ) in population ?.
We first present a loose lower bound that is attainable under only the bridging
assumptions discussed thus far, and we then add a final bridging assumption
that will often yield a tighter bound.
Given the bridging assumptions presented thus far, the tightest obtain-
able bound on Ψ(P 0,F? ) is given by the solution to the following optimization
problem:
Minimize
E0? [g(W )]
E0?[f(W )]
in f, g :W → [0, 1]
subject to λ0(W ) ≤ f(W ) ≤ υ0(W ), 1− g(W )
f(W )
≥ VE0−(W ),
where we use the convention that x/0 = 0 if x = 0 and x/0 = +∞ if x > 0. We
now argue that the solution to this problem is undesirably loose in general, and
that a further restriction will generally yield a tighter bound. For simplicity,
we give the argument in the special case where one is unwilling to assume
a lower bound on the unvaccinated risk so that λ0 ≡ 0. We then provide
an alternative optimization problem that will typically give a tighter (larger)
lower bound, present a closed-form solution to this new optimization problem,
and finally we show why the above optimization problem is undesirably loose
even in the case that λ0 is not the constant function zero. To ease discussion,
the remainder of this paragraph supposes that there exists a w− ∈ W such
that P 0? {VE0−(W ) = VE0−(w−)} > 0 and P 0? {VE0−(W ) < VE0−(w−)} = 0, i.e.
that VE0−(w−) is equal to the minimal value of VE0−(w) on W . In this case
one can quickly see that a w 7→ f(w) optimizing the above is positive at
w− and is zero everywhere else and the corresponding w 7→ g(w) is equal to
f(w−) VE0−(w−) at w− and 0 everywhere else, so that at this f, g we have that
1− E0?[g(W )]E0?[f(W )] = VE
0−(w−).
To overcome this problem, we will add an interpretable constraint to the
optimization problem. For each µ > 0 in the unit interval, we give a lower
bound on Ψ(P 0,F? ) that is valid if µ is equal to the marginal unvaccinated risk
E0?[E
0,F
? [Y |A = 0,W ]]. Each µ-specific lower bound can then be interpreted as
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valid provided the already stated bridging assumptions hold and µ is equal to
the the marginal unvaccinated risk. We derive our lower bound for Ψ(P 0,F? )
by finding the worst-case conditional unvaccinated risk, namely by solving the
following optimization problem:
Minimize
E0? [g(W )]
E0?[f(W )]
in f, g :W → [0, 1]
subject to E0?[f(W )] = µ, λ0(W ) ≤ f(W ) ≤ υ0(W ), 1−
g(W )
f(W )
≥ VE0−(W ).
The solution to our earlier problem in the special case where λ0(w) is always
zero, namely f(w−) > 0 and f(w) = 0 for w 6= w−, will fail to satisfy the
constraint µ = E0?[f(W )] once µ is large enough.
We now introduce notation to express a solution to our refined optimization
problem. We define all of these quantities at P0, but the definitions at general
P ′ ∈M are completely analogous. For each β :W → [0, 1] and w ∈ W , let
URβ(P0)(w) , λ0(w) + [υ0(w)− λ0(w)] β(w) , URβ,0(w).
The set of all unvaccinated risk functions allowed by our bounds λ0, υ0 is equal
to {URβ,0 : β}. For each URβ,0, the marginal unvaccinated risk is given by
Ωβ(P0) , E0?
[
URβ,0(W )
]
, ωβ,0.
We also define
Γβ(P0) , E0?
[
URβ,0 VE0−(W )
]
, γβ,0.
Often ωβ,0 − γβ,0 can be interpreted as a marginal vaccinated risk, though
there is not in general any guarantee that this quantity is bounded in [0, 1].
We discuss this subtlety further following Lemma 1.
We now define β0 : W → [0, 1], which we will shortly show to be a β
indexing the worst-case unvaccinated risk. The function β0 assigns unvacci-
nated risk according to the upper bound υ0 to as many covariate strata with
small VE0−(w) as allowed by the marginal unvaccinated risk constraint µ. This
threshold is defined by
Θ(P0) , sup
{
θ ∈ R : ω
w 7→1{VE0−(w)<θ},0 ≤ µ
}
, θ0,
where sup ∅ = −∞ by convention. Let βη , w 7→ 1{VE0−(w)<θ0}+η 1{VE0−(w)=θ0},
and define η0 to be the smallest element of the set argminη∈[0,1]
(
ωβη ,0 − µ)2.
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Let β0 , βη0 . One can show that, if E0?[λ0(W )] ≤ µ ≤ E0?[υ0(W )], then
ωβ
0,0 = µ.
Finally, we define the bridging parameter that we will aim to estimate at
P0, and note that the definition at general P ′ is entirely analogous:
Φ(P0) , Γ
β0(P0)
Ωβ0(P0) =
γβ
0,0
ωβ0,0
, φ0,
where we remind the reader of the dependence of β0 on P0. We now establish
that φ0 provides a valid lower bound for Ψ(P 0,F? ).
Lemma 1. Suppose B1, B2, B3, and B4 hold. If µ = E0?[E
0,F
? [Y |A = 0,W ]],
then Ψ(P 0,F? ) ≥ φ0.
The proof of Lemma 1 is given in Appendix B.1. Typically the lower
bound φ0 will be attainable, in the sense that there exists a distribution for
population ? satisfying B1, B2, and µ = E0?[E
0,F
? [Y |A = 0,W ]] such that the
marginal vaccine efficacy is equal to φ0. In this case φ0 is the solution to the
refined optimization problem presented earlier in this section. In particular,
it will often be the case that a distribution with marginal vaccine efficacy
φ0 is that with unvaccinated risk E0,F? [Y |A = 0, w] = URβ
0,0(w) and vaccine
efficacy curve w 7→ VE0−(w). The only time no such distribution exists is when
the claimed vaccinated risk w 7→ URβ0,0(w)[1 − VE0−(w)] fails to obey the
bounds of the model, which may be larger than 1 if (i) URβ
0,0(w) is large and
1−VE0−(w) > 0 or (ii) 1−VE0−(w) is large. In practice it is unlikely that either
of these quantities will be large: the unvaccinated risk will generally be small
for rare outcomes, and the vaccine efficacy within a biomarker stratum will
rarely be extremely negative, as this indicates that the vaccine is extremely
harmful within this stratum and represents a situation where the bridging
application would likely not be of interest and hence the method would not be
applied.
Remark 1. Returning to our first optimization problem in this section, i.e.
the optimization problem that did not include the constraint E0?[f(W )] = µ, we
see that the minimum occurs by minimizing the solution to the latter problem
over all values of µ > 0. We then see that the solution to the first optimization
problem is equal to the lowest point on our µ-dependent curve, so that indeed
the added restriction will generally improve our bound. For this observation
to be true, one might anticipate that the reason that the solution to the first
optimization problem is VE−(w−) in the case where the unvaccinated risk lower
bound is the constant function zero, i.e. λ0 ≡ 0, is that φ0µ is monotonic in µ,
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where we write φ0µ to emphasize the dependence of φ
0 on µ. Indeed, we show
in Lemma A.1 in Appendix B.1 that φ0µ is monotonically nondecreasing in µ in
this case. This observation enriches the interpretation of the lower bound φ0µ′
when λ0 ≡ 0, since in this case φ0µ′ can be interpreted as a valid lower bound for
the marginal vaccine efficacy provided µ′ ≤ µ = E0?[E0,F? [Y |A = 0,W ]] and the
conditions of Lemma 1 hold at µ: as φ0µ′ ≤ φ0µ and φ0µ lower bounds the vaccine
efficacy, φ0µ′ must also lower bound the vaccine efficacy. Thus, in this special
case, φ0µ′ is a valid lower bound whenever µ
′ ≤ E0?[E0,F? [Y |A = 0,W ]]. 2
3 First-order expansion of lower bound
In this section, we present a result that we will use to derive a first-order
expansion of the parameter Φ. This expansion plays a key role in our esti-
mation procedure. Before presenting this result, we quickly define a gradient
for a general parameter Π : M → R in the S + 1 sample problem. We
only define this and other gradients in this section at P0, but the exten-
sion to a general P ′ only requires notational changes. For each s ∈ S, let
hs : Os → R satisfy Es[hs(Os)] = 0 and supos |hs(os)| ≤ 1. For  ∈ (−1, 1),
define dP

s
dP 0s
(os) = 1 + hs(os), s ∈ S. Let P , (P ? , P 1 , . . . , P S). We call
Π pathwise differentiable if, for s ∈ S, there exist functions ∇Π0s ∈ L2(P 0s )
satisfying
d
d
Π(P)
∣∣∣∣
=0
=
∑
s∈S
∫
∇Π0s(os)hs(os)dP 0s (os).
Our pathwise differentiability result will require one of the following three
regularity conditions on the marginal distribution of W in population ?. The
first is given below.
C1) E0?[λ0(W )] < µ < E
0
?[υ
0(W )] and, for all θ in a neighborhood of θ0,
0 < lim inf
t→0
P 0? {VE0−(W ) < θ + t} − P 0? {VE0−(W ) < θ}
t
≤ lim sup
t→0
P 0? {VE0−(W ) < θ + t} − P 0? {VE0−(W ) < θ}
t
<∞.
The above implies both that θ0 is finite and that ωβ
0,0 = µ.
For the choice of µ to be feasible, i.e. for it to be possible that P 0,F? ∈
M? satisfies both B2 and E0?[E0,F? [Y |A = 0,W ]] = µ, we generally need that
11
E0?[λ0(W )] ≤ µ ≤ E0?[υ0(W )]: one cannot otherwise have both E0?[E0,F? [Y |A =
0,W ]] = µ and λ0(w) ≤ E0,F? [Y |A = 0, w] ≤ υ0(w) for all w. Nonetheless, it is
useful to understand the first-order behavior of the parameter Φ for all values
of µ since the marginal distribution of W ∼ P 0? must be estimated in practice.
Thus, we offer conditions for both the case that µ is so large that it violates
the upper bound on E0,F? [Y |A = 0, w], i.e. µ > E0?[υ0(W )], and then for the
case that µ is so small that it violates the lower bound on E0,F? [Y |A = 0, w],
i.e. µ < E0?[λ0(W )].
C1’) The upper bound is too small: E0?[υ0(W )] < µ.
C1”) The lower bound is too large: E0?[λ0(W )] > µ.
Remark 2. None of these three conditions (C1, C1’, C1”) allow P 0? (VE
0−(W ) =
θ0) > 0. This is closely related to the non-pathwise differentiability of many pa-
rameters of interest in personalized medicine under so-called exceptional laws
(Robins, 2004; Luedtke and van der Laan, 2016a), i.e. distributions for which
the conditional average treatment effect is zero in some positive probability
stratum of measured covariates. The condition that P 0? {VE−(W ) = θ0} = 0
may be unlikely to hold in settings where θ0 is below the lower limit of quan-
tification of W , namely because small values of W indicate a true value of zero
for the biomarker and any deviation from zero is due to noise. If θ0 falls below
the lower limit if quantification, then we expect that P 0? {VE0−(W ) = θ0} > 0
and indeed we will have no guarantee that Ψ(P 0,F? ) ≥ φ0. In Appendix E.2, we
describe an alternative bridging parameter that requires that W is univariate
and VE0− is monotonic rather than that P 0? {VE0−(W ) = θ0} > 0.
Finally, we note that, while the conditions of Theorem 2 are sufficient for
the pathwise differentiability of Φ, they are not necessary. For example, if W
is discrete and takes on a finite number of values, then one can give conditions
under which Φ is pathwise differentiable even if P 0? (VE
0−(W ) = θ0) > 0, though
these conditions still appear to require that only one w ∈ W satisfies VE0−(w) =
θ0. We do not consider this subtle case further in this work. 2
The following objects, defined for each s = 1, . . . , S, will be useful for
establishing the gradient of Φ:
Dβ,P
0
UR,s(os) , [`s(w) + β(w){us(w)− `s(w)}]
1{a=0}
P 0s (a|w)
(
y − E0s[Y |a, w]
)
, β :W → R,
DP
0
VE,s(os) ,
vs(w)
[
1{a=0}VE0−(w)− 1{a=1}
]
P 0s (a|w)
[
v0(w)d(0, w) +
∑S
s′=1 vs′(w)E
0
s′ [Y |A = 0, w]
](y − E0s[Y |a, w]).
(1)
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For ease of notation, we let Dβ,0UR,s , D
β,P0
UR,s and D
0
VE,s , DP
0
VE,s. For any
β :W → [0, 1], define
∇Ωβ,0? (o?) = URβ,0(w)− ωβ,0,
∇Ωβ,0s (os) =
dP 0?
dP 0s
(w)Dβ,0UR,s(os), s = 1, . . . , S,
∇Γβ,0? (w) , URβ,0(w) VE0−(w)− Γβ(P0),
∇Γβ,0s (os) ,
dP 0?
dP 0s
(w)
[
Dβ,0UR,s(os) VE
0−(w) + URβ,0(w)D0VE,s(os)
]
, s = 1, . . . , S.
We now give a theorem establishing that the parameter Φ is pathwise differ-
entiable at P0.
Theorem 2. If B3 and B4 hold and either C1, C1’, or C1” holds, then Φ is
pathwise differentiable and, for each s ∈ S, the P 0s gradient is given by
∇Φ0s(os) =

∇Γβ0,0s (os)
ωβ0,0
− θ0∇Ω
β0,0
s (os)
ωβ0,0
, if E0?[λ0(W )] < µ < E
0
?[υ
0(W )],
∇Γβ0,0s (os)
ωβ0,0
− γβ0,0∇Ω
β0,0
s (os)
[ωβ0,0]2
, otherwise.
.
The proof of Theorem 2 is given in Appendix B.2.
Remark 3. Though we have assumed that υ0(w) − λ0(w) is bounded away
from zero, we will now briefly remark on a violation of this assumption, namely
the case that `s ≡ us so that υ0 ≡ λ0. In this case the gradients of Φ are
given by the same expression as in Theorem 2 for the case where θ0 = +∞
so that P 0? (VE
0−(W ) < θ0) = 1. The estimation scheme that we present
in the next section will remain valid even when υ0 ≡ λ0 provided one uses
the appropriate gradients, namely the gradients from Theorem 2 when θ0 =
+∞, when constructing the confidence lower bound. If VE0,F? = VE0−, then
the marginal vaccine efficacy in population ? is point identified, and so our
procedure is analogous to the earlier work by Rudolph and van der Laan
(2016), with the slight distinction that we focus on a multiplicative rather
than additive parameter. 2
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4 Estimation
4.1 Conditional vaccine efficacy not necessarily constant
across s = 1, . . . , S
We first consider the case where we do not assume that VE01 ≡ . . . ≡ VE0S,
but rather make the weaker assumption B1 for a prespecified set of functions
v0, v1, . . . , vS.
4.1.1 Estimator. Below and throughout, we let Qns denote the empirical
distribution of the observations Os[1], . . . , Os[ns] for each s ∈ S. We also de-
note the expectation operator under Pn by Ens . We also refer to parameters
evaluated at the collection of distributions Pn rather than parameters evalu-
ated at P0 by replacing the superscript zero by superscript n, e.g. we write
υn , Υ(Pn) rather than υ0 , Υ(P0). We do the same for gradients, e.g.
∇Φns rather than ∇Φ0s. When we define objects that may be confused with
parameter mappings applied directly to Pn, we add a hat: in particular, we
will define β̂n, η̂n, θ̂n, ω̂β̂
n,n, γ̂β̂
n,n, and φ̂n.
Below we present an estimation scheme to be used when either (i) the cho-
sen `s(w) is a constant multiple of the chosen us(w), where the multiple is
independent of s and w, or (ii) the chosen `s ≡ 0 for all s so that λ0 ≡ 0.
In Appendix D, we present alternatives to the targeted minimum loss-based
(TMLE) steps 2, 3, and 4 that replace the univariate logistic regression by a
bivariate logistic regression. The bivariate regression is inappropriate when
(i) holds because the two predictors in the proposed logistic regression will be
perfectly correlated, and so, while analytically correct, the method may en-
counter numerical challenges in practice. When (ii) holds running the bivariate
regression presented in the appendix is simply unnecessary because the latter
covariate is always zero. The proof of asymptotic linearity of our estimation
scheme assumes that the user runs the appropriate estimation scheme, either
the below or that in Appendix D.
1. Let (a, w) 7→ En,inits [Y |a, w], w 7→ P n,inits (A = 1|w), and w 7→ dP
n,init
?
dPn,inits
(w)
represent estimates of (a, w) 7→ E0s[Y |a, w], w 7→ P 0s (A = 1|w), and
w 7→ dP 0?
dP 0s
(w), respectively.
2. Fit a univariate logistic regression with outcome (ys[i] : s = 1, . . . , S; i = 1, . . . , ns),
covariate
(
1{as[i]=0} us(w)
nsP
n,init
s (A=0|ws[i])
dPn,init?
dPn,inits
(ws[i]) : s = 1, . . . , S; i = 1, . . . , ns
)
, and
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fixed, subject-level intercept
(
logit
(
En,inits [Y |A = 0, ws[i]]
)
: s = 1, . . . , S; i = 1, . . . , ns
)
.
Denote the fitted coefficient in front of the covariate by n.
3. For each s = 1, . . . , S, let (a, w) 7→ En,ns [Y |a, w] denote the function
(a, w) 7→ logit−1
[
logit
(
En,inits [Y |a, w]
)
+ n
1{a=0} us(w)
nsP
n,init
s (A = 0|w)
dP n,init?
dP n,inits
(w)
]
.
4. Let Pn = (P n? , P n1 , . . . , P ns ) denote any collection of distributions satis-
fying that, for all (a, w), Ens [Y |a, w] = En,ns [Y |a, w], P ns (A = 1|w) =
P n,inits (A = 1|w), and dP
n
?
dPns
(w) = dP
n,init
?
dPn,inits
(w).
5. For each β :W → [0, 1], let ω̂β,n , ωβ,n +∑s∈S Qns∇Ωβ,ns , and note that
ω̂β,n rewrites as Qn? UR
β,n +
∑S
s=1Q
n
s∇Ωβ,ns .
6. Let θ̂n , sup{θ : ω̂w 7→1{VE
n−(w)<θ},n ≤ µ}, where sup ∅ = −∞.
7. Let η̂n be the smallest element of the set argminη∈[0,1]
(
ω̂βη ,n − µ)2, where
βη , w 7→ 1{VEn−(w)<θ̂n}+η 1{VEn−(w)=θ̂n}.
8. Let β̂n , βη̂n .
9. Estimate γβ̂
n,0 with
γ̂β̂
n,n , γβ̂n,n +
∑
s∈S
Qns∇Γβ̂
n,n
s
= n−1?
n?∑
i=1
URβ̂
n,n(w?[i]) VE
n(w?[i]) +
S∑
s=1
Qns∇Γβ̂
n,n
s .
10. Estimate φ0 with φ̂n , γ̂β̂
n,n
ω̂β̂n,n
.
The initial estimates in Step 1 can be obtained by any methods deemed appro-
priate by the investigators. We encourage the use of data adaptive regression
and machine learning techniques to estimate these features of P0, since the
study of our estimator in the next section relies on consistency conditions
given in Appendix A that are most plausible when one does not restrict the
estimates in Step 1 to those obtained by classical parametric models.
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Remark 4. The above represents a hybrid between a TMLE and a one-step
estimator. When θ0 = ±∞, it uses a TMLE to estimate ωβ0,0 (Steps 2, 3, 4).
It uses a one-step estimator for γβ̂
n,0 (Step 9) and to correct the bias of ωβ,n for
ωβ,0 when defining β̂n (Step 5). For Step 9, one could specify a fluctuation of
the initial estimate of P0 with score given by the sum of the empirical means of
the S+1 gradients to replace the one-step estimator by a TMLE to have a full-
fledged TMLE. One could analyze this estimator similarly to that of our hybrid
estimator (van der Laan and Rose, 2011). The TMLE is preferred to a one-step
estimator in many problems because it yields a plug-in estimator of the form
γβ̂
n,n for some distribution Pn, and is thus guaranteed to respect the known
bounds on γβ̂
n,0. Most fluctuation submodels indexing the TMLE appear to
require iterating the fluctuation step until convergence. Alternatively, one
could use the newly developed universal least favorable submodel, which has
the advantage of always being fit in one step (van der Laan and Gruber, 2016).
We leave the development of full-fledged (non-hybrid) TMLEs for this problem
to future work. 2
Remark 5. The upper and lower bounds υ0 and λ0 on the conditional unvac-
cinated risk imply bounds on the plausible range of values of µ. These bounds
can be estimated using ω̂β,n, where β is taken to be the constant function re-
turning one and zero, respectively. Under the same conditions as those given
in the upcoming Theorem 3, one can show that, for each of these choices of β,
ω̂β,n−ωβ,0 ≈∑s∈S(Qns −P 0s )∇Ωβ,0s , so that confidence intervals for υ0 and λ0
can be developed using the analogous asymptotic normality results to those
to be used to develop a confidence lower bound for φ0 in Section 4.1.3. 2
4.1.2 Asymptotic linearity of our estimator. In the appendix we give
several additional assumptions used to establish that the estimator φ̂n satisfies
a multiple sample version of asymptotic linearity, namely that
φ̂n − φ0 =
∑
s∈S
(Qns − P 0s )∇Φ0s + oP (n−1/2min ), (2)
where, for nmin , min{ns : s ∈ S}, we use oP (n−1/2min ) to denote a random
variable Xn that is a function of all of the n observations from Populations
?, 1, . . . , S with the property that, for each δ > 0, the event {n1/2minXn > δ}
has probability converging to zero whenever nmin grows to infinity. We discuss
those conditions below the theorem.
The following theorem establishes that our estimator minus the truth be-
haves as a sum of empirical means across the S + 1 data sets.
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Theorem 3. If B3, B4, C2, C3, C4, and C5 hold and either C1, C6, and C7
hold, C1’ holds, or C1” holds, then φ̂n satisfies (2).
The proof of Theorem 3 is given in Appendix B.3. We now summarize
the additional conditions used in the theorem. Condition C2 requires that the
initial estimate of P0 is consistent and that certain remainder terms converge
at a sufficient rate, namely oP (n
−1/2
min ). Only requiring remainder terms to
behave like oP (n
−1/2
min ) makes our conditions on estimates of parameters from
a full efficacy trial s more plausible if ns  nmin, since we typically expect
these parameters to converge at an n
−1/2
s rate in a parametric model and a
slower rate in a nonparametric model, but the slower rate may still be much
faster than n
−1/2
min . Furthermore, the fact thatW is univariate leads us to believe
that, under some smoothness, we expect the nonparametric rate for estimating
the needed functionals of Pn to be only slightly slower than the parametric
rate. Conditions C3 and C4 represent an empirical process condition and mild
consistency condition on the initial estimate Pn. Condition C6 ensures that
the estimate β̂n of β0 satisfies ω̂β̂
n,n ≈ µ, where ω̂β̂n,n is a one-step estimate of
ωβ̂
n,0. This is to be expected under C1 given that ωβ
0,0 = µ in this case, much
as we expect the empirical cumulative distribution function evaluated at the
sample median to be equal to 1/2+oP (n
−1/2). In fact, we often expect ω̂β̂
n,n to
be exactly equal to µ, and this can be formally checked in any given application
by looking at ω̂β̂
n,n. Condition C7 requires that VEn− estimates VE0− sufficiently
well so that URβ̂
n,0 is approximately equal to the worst-case unvaccinated risk
function URβ
0,0. Appendix C relates this condition to the margin conditions
appearing in the classification literature. Condition C5 simply states that the
estimate of the vaccine efficacy curve w 7→ VE0−(w) is bounded away from
negative infinity, which is plausible given that w 7→ VE0−(w) is bounded under
B4.
4.1.3 Constructing a lower confidence bound. We now describe how
Theorem 3 allows the construction of a lower confidence bound for the vaccine
efficacy lower bound φ0. For all s ∈ S, let σ2s , E0s[∇Φ0s(O)2], i.e. the
variance of ∇Φ0s(O) when O ∼ P 0s . Accepting slight notational overload,
we define σ2n ,
∑
s∈S
nmin
ns
σ2s . We propose using φ̂
n − 1.64n−1/2min σˆn as a lower
confidence bound for φ0, where σˆn ,
∑
s∈S
nmin
ns
σˆ2s for empirical estimates
σˆ2s , Qns [∇Φns − Qns∇Φns ]2 of σ2s . Our lower confidence bound on φ0 deviates
from φ̂n by the order n
−1/2
min σn. As σn <
∑
s∈S σ
2
s < ∞ and φ̂n deviates from
φ0 on the order O(n
−1/2
min ) by our asymptotic linearity result, the deviation of
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our lower confidence bound from φ0 is of the order of the inverse square root
of the smallest trial. Given that the trials in Populations 1, . . . , S will often
have been efficacy studies, we will often expect the smallest sample to be of
subjects drawn from population ?.
We can repeat the above procedure for a range of plausible µ values and
report a graph of how the lower bound varies with the choice of µ. We remind
the reader that the estimate φ̂n and each σˆ2s rely on µ, and so these values
must be recalculated for each choice of µ. Figure 2 from our simulation study
suggests an informative way to display the vaccine efficacy lower bound, with
the “average lower bound” y-axis (averaged across Monte Carlo replications
of our simulation) replaced by the estimated lower bound. Given a range U of
plausible values for µ, one can read a lower uncertainty interval (Vansteelandt
et al., 2006) for the marginal vaccine efficacy Ψ(P 0,F? ) in population ? by
looking at the smallest µ-specific confidence lower bound across all µ ∈ U .
We now justify our lower confidence bound. Note that (2) rewrites as
√
nmin[φ̂
n − φ0]
σn
=
∑
s∈S
ns∑
i=1
√
nmin
nsσn
∇Φ0s(Os[i]) + oP (1). (3)
For each s, observe that
Var0s
[√
nmin
nsσn
∇Φs(Os[i])
]
=
1
ns
n−1s σ
2
s
[n−1? σ2? +
∑S
s′=1 n
−1
s′ σ
2
s′ ]
.
The latter fraction on the right-hand side is bounded between 0 and 1. Thus
the variance on the left shrinks at rate O(n−1s ). The above and the inde-
pendence of all of the observations also shows that the double sum on the
right-hand side of (3) has variance 1.
These two facts readily allow one to show that the conditions of the Lin-
deberg central limit theorem hold, thereby establishing that
√
nmin[φ̂
n−φ0]
σn
con-
verges to a standard normal distribution (Billingsley, 1999). It follows that a
valid 95% level lower confidence bound for φ0 is given by φ̂n− 1.64n−1/2min σn. In
practice, σn is not known, but we can estimate it with σˆn. Glivenko-Cantelli
conditions on the functions ∇Φns ensure that σˆ2n → σ2n in probability, and un-
der this convergence Slutsky’s theorem then ensures that a 95% lower bound
for φ0 is given by φ̂n − 1.64n−1/2min σˆn.
4.1.4 Intuition for the estimator’s construction and sketch of asymp-
totic linearity proof. Our estimator is a hybrid of a TMLE and a one-step
estimator. Before discussing our specific estimator, we give some intuition by
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discussing one-step estimation of a general pathwise differentiable parameter
Π : M → R. Suppose that Pn is an initial estimate of P0 and we wish to
estimate pi0 , Π(P0). One possible estimate is obtained via plug-in estima-
tion: pin , Π(Pn). If Pn is a good estimate of P0, often in the sense that
certain regression functions under Pn are close to the corresponding regres-
sions under P0, then we generally expect that pin − pi0 ≈ −∑s∈S P 0s∇Πns ,
where ∇Πns are gradients of Π evaluated at Pn. It will often be the case that
the right-hand side of this approximation is not OP (n
−1/2
min ), and thus that pi
n
converges to pi0 at a slower than n
−1/2
min rate. In an effort to improve the initial
estimate pin, a one-step estimator adds the empirical version of
∑
s∈S P
0
s∇Πns
to the initial estimate pin, i.e. one uses as estimate pin , pin +
∑
s∈S Q
n
s∇Πns ,
so that pin − pi0 ≈ ∑s∈S(Qns − P 0s )∇Πns . Under empirical process conditions,
one can replace the gradients ∇Πns under Pn by the gradients ∇Π0s under P0
so that pin − pi0 ≈ ∑s∈S(Qns − P 0s )∇Π0s and it is possible to apply a central
limit theorem to understand the behavior of a scaled version of the one-step
estimator minus the truth. Typically TMLEs follow a similar derivation, but
the initial estimate Pn of P0 is carefully selected so that the bias correction∑
s∈S Q
n
s∇Π0s is small or zero.
The remainder of the discussion is focused on our proposed estimator.
Steps 2, 3, and 4 are designed to ensure that the score
∑S
s=1Q
n
s∇Ωβ,ns is
equal to zero when β ≡ 1, which is an important score equation to solve if
θ̂n = +∞. If each `s(w) is a constant multiple of us(w) or if each `s ≡ 0, then
the same score equation is equal to zero when β ≡ 0, which is an important
score equation to solve when θ̂n = −∞. Otherwise, Steps 2’, 3’, and 4’ in
Appendix D ensure that the score equation is solved at both β ≡ 0 and β ≡ 1.
If θ̂ = +∞, then 1{VEn−(w?[i])<θ̂n} = 1 for all i = 1, . . . , n? so that the preceding
argument implies that
∑S
s=1Q
n
s∇Ωβ̂n,ns = 0 and Step 5 trivially yields that
Qn?∇Ωβ̂n,n? = 0. Similarly, θ̂n = −∞ implies that
∑S
s=1Q
n
s∇Ωβ̂n,ns = 0.
We now discuss the choice of β̂n. For each β, ω̂β,n is a one-step estimator
for ωβ,0. It is therefore not surprising that, under the conditions given in
Appendix A, ω̂β,n = ωβ,0 + OP (n
−1/2
min ). If θ
0 is finite, then one can show
θ̂n ≈ θ0 (see Lemma A.14 in Appendix C). Furthermore, if µ is too large
so that θ0 = +∞, then our conditions imply that θ̂n = ∞ with probability
approaching one (see Lemma A.9 in the Appendix B.3), and an analogous
result holds if µ is too small.
Given an estimate of β̂n, it remains to estimate φ0. We show in Ap-
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pendix B.3 that
φ̂n − φ0 ≈ γ̂
β̂n,n − γβ̂n,0
ωβ0,0
− γ
β0,0
[ωβ0,0]2
[
ω̂β̂
n,n − ωβ0,0
]
+
γβ̂
n,0 − γβ0,0
ωβ0,0
.
For the first term on the right, we note that, γ̂β,n is a one-step estimator for
γβ,0 for each β, and so it is not surprising that this estimator is asymptoti-
cally linear for each β. Furthermore, the fact that β̂n converges to the fixed
quantity β0 suggests that these same asymptotic linearity statements should
hold with β replaced by β̂n (can be formally shown via empirical process ar-
guments). Under C1 and C6, ω̂β̂
n,n ≈ µ = ωβ0,0 so that the second term above
is negligible. Under C1’ or C1”, the β̂n is correctly specified with probability
approaching one so that analyzing the second term is like analyzing the one-
step estimator ω̂β
0,n of ωβ
0,0, which is asymptotically linear under reasonable
conditions. Additionally, C1’ or C1” implies that the final term above is equal
to zero with probability approaching one. For the final term above under C1,
we note that
γβ̂
n,0 − γβ0,0 = β0
[
ωβ̂
n,0 − ωβ0,0
]
+
{
γβ̂
n,0 − γβ0,0 − β0
[
ωβ̂
n,0 − ωβ0,0
]}
,
where the latter term is negligible by assumption C7 (though a more inter-
pretable sufficient condition is given in Appendix C). We establish the behavior
of ωβ̂
n,0 − ωβ0,0 by using that ω̂β̂,n ≈ µ = ωβ0,0, and so it suffices to study the
behavior of −[ω̂β̂n,0 − ωβ̂n,0]. The study of this term is standard since ω̂β,0 is
a one-step estimator of the β-specific parameter ωβ,0.
4.2 Conditional vaccine efficacy constant across s = 1, . . . , S
The lower bound in the above section relies on the validity of the bridging
assumption B1, which is indexed by d and v0, v1, . . . , vS. Suppose that the
following condition holds:
B5) The vaccine efficacy curve w 7→ VEs(w) is constant across trials s =
1, . . . , S and the chosen v0 ≡ 0.
Choosing v0 ≡ 0 indicates that the user believes that the vaccine efficacy curves
in the completed trials lower bound the vaccine efficacy curve in population ?.
We now show that the above condition allows one to choose v , (vs : s =
1, . . . , S) to maximize statistical efficiency for estimating our lower bound. In
what follows we make the dependence of w 7→ VE0−(w) on v explicit by writing
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VEv,0− . The result relies on the fact that VE
v,0
− is invariant in v. In particular,
for each w we have that
VEv,0− (w) =
∑S
s=1 vs(w)Es[Y |A = 0, w] VE0s(w)∑S
s=1 vs(w)Es[Y |A = 0, w]
= VE01(w)
∑S
s=1 vs(w)Es[Y |A = 0, w]∑S
s=1 vs(w)Es[Y |A = 0, w]
,
which is equal to VE01(w). Thus, under B5, if B1 holds for some set of functions
v, then it holds for all v. While the above derivation implies that the lower
bound parameter Φ is also invariant to v, the same is not true of the gradients
presented in Theorem 2. As the gradient determines the efficiency of our
estimator, and therefore the width of our confidence interval, it follows that
one can choose v to (approximately) maximize the efficiency of our procedure
provided B5 holds. Let σˆ2n(v) and σ
2
n(v) respectively denote the values of σˆ
2
n
and σ2n defined in Section 4.1.3, but now making the dependence on v explicit
in the notation. If the consistency conditions of Theorem 3 hold uniformly
over all v in some class V , then one expects that
sup
v∈V
|σˆ2n(v)− σ2n(v)| → 0. (4)
As σˆ2n(v) can be written as an empirical mean of random functions, the primary
condition that one needs to add to Theorem 3 for this convergence to be valid
is that V is not too large, namely that functions in the sets in V belong to
a Glivenko-Cantelli class. We will return to this requirement shortly. For
now, suppose that we have selected a class V small enough so that (4) is
plausible. One can then select vn as the minimizer of σˆ
2
n(v) over v ∈ V . If V
satisfies a more restrictive condition, namely that the functions in the sets it
contains are Donsker, then we expect that we can run the estimator described
in Section 4.1.1 at the selected vn and report the lower confidence bound as
defined in Section 4.1.3. A simple suggestion for a class V that satisfies the
conditions of the previous theorem is that V consists of constant functions,
namely each vs(w) ∈ [0, 1] does not depend on w. One could alternatively
parameterize vs using, e.g., a linear logistic regression formulation so that
vs(w) ∝ logit−1(β0 + β1w) to further improve efficiency.
The arguments that we have provided here are only a sketch: more work
would be needed to make them precise, though these arguments are fairly
standard when studying M-estimators (van der Vaart and Wellner, 1996), and
a detailed study specific to an estimator with a nuisance parameter selected to
minimize the variance were given in Rubin and van der Laan (2008). A careful
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analysis would show that, when B5 holds and V is not too large, the conditions
needed to ensure the validity of the procedure discussed in this section are
not much stronger than the conditions needed to establish the validity of a
procedure at fixed v. Indeed, in Section 5 we show via simulation that this
procedure yields less conservative lower bounds while still maintaining nominal
coverage.
5 Simulation
5.1 Simulation settings
We evaluated the performance of our method via simulation in R (R Core
Team, 2014). We have S = 2 completed efficacy trials in our simulation. We
first run our simulation without missingness in the biomarker W , and then we
simulate data from a two-phase sampling scheme.
Let Z be a standard normal random variable. The marginal distribution
of W has the same distribution as logit−1(Z−2) when s = 1, logit−1(5[Z−1])
when s = 2, and logit−1(2[Z − 1/2]) when s = ?. All trials assign treatment
with probability 1/2, regardless of the value of baseline covariates. The vaccine
efficacy is the same across Populations 1 and 2. In particular, both have vaccine
efficacy
VE(w) = 1− logit
−1 (−1− w − 3[0.3 + (w − 0.2)+])
logit−1 (−1− w) ,
where x+ denotes the positive part of x. As E0s[Y |A = 1, w] equals [1 −
VE(w)]E0s[Y |A = 0, w], it suffices to define E0s[Y |A = 0, w] for each of the
three trials. We let E01[Y |A = 0, w] = logit−1 (−1− w) and E02[Y |A = 0, w] =
logit−1 (−1) ≈ 0.27.
We consider two sample size settings, namely (n?, n1, n2) equal to
(100, 2000, 2000) and (200, 4000, 4000). We respectively refer to these sample
sizes as the “Smaller Sample Size” and “Larger Sample Size” in our figures.
We use three choices for the coefficients indexing our unvaccinated risk lower
and upper bounds. The first setting, labeled “Loosest” in our figures, sets
`s ≡ us ≡ 0, s = 1, 2, and `0 ≡ 0, u0 ≡ 1. The second, labeled “Moderate” in
our figures, sets `s ≡ 0.25 and us ≡ 0.75, s = 1, 2, and `0 ≡ u0 ≡ 0. The third,
labeled “Tight” in our figures, sets `s(w) = 0.4 and us(w) = 0.6, s = 1, 2, and
`0 ≡ u0 ≡ 0.
We suppose that the user a priori believes that VE0,F? (w) ≥ VE1(w) and
that VEs(w) is invariant in s. In this case v0(w) = 0, while w 7→ VE0−(w) is in-
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variant in the choice of v. We implement the version of our estimator presented
in the main text since `s(w) is a multiple of us(w) for all simulation settings,
both for fixed v1(w) = v2(w) = 1/2, all w, indexing w 7→ VE0−(w) and also
for the procedure described in Section 4.2 that adaptively selects a w-invariant
convex combination v1(w), v2(2) to maximize the estimator’s precision. We re-
spectively refer to these estimation schemes as “Fixed” and “Adaptive” in our
figures. The marginal distributions of the biomarker within each population
are estimated using a ratio of kernel density estimates as provided by the ks
package (Duong, 2016), with the option unit.interval set to TRUE so that
the estimator respects the bounds on the biomarker W and the bandwidth
selected according to the univariate plug-in selector presented in ?. The ratio
is then standardized so that the empirical mean of each s-specific estimate of
dP 0?
dP 0s
has empirical mean 1 within the sample of observations from Trial s. Al-
though the probability of treatment given covariates is known in each trial, we
estimate these quantities because of the known efficiency gains resulting from
doing so (van der Laan and Robins, 2003). In particular, we regress A against
W using the ensemble algorithm found in the SuperLearner package (van der
Laan et al., 2007; Polley and van der Laan, 2013), and provide the algorithm
with a candidate library containing SL.glm and SL.glm.interaction. We
estimate the outcome regressions by regressing Y against A and W using the
SuperLearner package, using a candidate library containing SL.mean, SL.glm,
SL.glm.interaction, SL.step.interaction, SL.gam, and SL.nnet.
We then repeat our simulation with missingness in the biomarker in the
completed efficacy trials via a 1:1 nested case:control sampling design. In
particular, we suppose that biomarker values are observed on all m cases (par-
ticipants with Y = 1), and, within each trial s, on a random sample of controls
of size m. We run the method described in Appendix E, first using the known
observation weights, and then estimating these weights by using the known
unity weights among cases and, among controls, running a logistic regression
of observation status against a linear interaction model of observation status
against an indicator for belonging to Trial s = 1, 2 and an observed covari-
ate X = logit−1[logit(W ) + Z], where Z is a standard normal. The covariate
X is meant to represent a biomarker that is inexpensive to measure on all
participants, but that is highly predictive of the biomarker W needed for the
bridging exercise.
The function VE0− used in our simulation is monotonic, and therefore the re-
sults in Appendix E.2 may be used to weaken the assumptions for our method’s
applicability. The results were nearly identical for this data generating distri-
bution and so are omitted.
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Figure 1: Coverage of our lower confidence bound for φ0, i.e. the lower bound
on the vaccine efficacy, in our simulation. Conducted at both smaller and
larger sample sizes, respectively with (n?, n1, n2) equal to (100, 2000, 2000)
and (200, 4000, 4000), and for different choices of `s and us, determining the
tightness of the unvaccinated risk bounds. Horizontal dashed lines drawn at
95% coverage.
5.2 Simulation results
Figure 1 demonstrates that our lower confidence bounds achieve approximately
95% or better coverage for the lower bound on the vaccine efficacy across
simulation settings and values of µ. The bound is generally conservative for the
Moderate and Tight settings. For a given data generating distribution, there
is one true value of the marginal unvaccinated risk µ0, and the interpretation
of our curve as a 95% lower confidence bound is valid if the lower bound
coverage is approximately 95% when µ = µ0. The methods that choose the
convex combination in the w 7→ VE0−(w) bridging parameter to minimize the
standard error had comparable coverage than the methods that used a fixed
convex combination.
Figure 2 demonstrates that the adaptive methods tend to have a slightly
higher average lower bound than the fixed methods that use a convex combi-
nation of (1/2, 1/2) for the VE bridging assumption. Given the approximately
appropriate coverage of both methods for the (typically conservative) lower
bound on the true vaccine efficacy, it seems prudent in practice to use the less
conservative adaptive approach.
In Appendix F, we display analogous plots for the fixed two-phase sampling
method. Results were similar for the adaptive method. These plots show that
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Figure 2: Average estimates (solid lines) and lower confidence bounds (dashed
lines) for φ0, i.e. the lower bound on the vaccine efficacy, in our simula-
tion. Conducted at both smaller and larger sample sizes, respectively with
(n?, n1, n2) equal to (100, 2000, 2000) and (200, 4000, 4000), and for different
choices of `s and us, determining the tightness of the unvaccinated risk bounds.
Black trend lines denote true (`s,us, µ)-specific lower bound.
the two-phase sampling procedure still maintains the desired coverage level,
with a moderate loss in precision in our setting. This is not surprising given
that the user has less data for the two-phase methods.
6 Discussion
We have presented a method for using data from completed efficacy trials
to partially bridge the vaccine efficacy to a new population. We first de-
veloped conditions that identify a population level parameter representing a
lower bound on the vaccine efficacy in the new population. We then provided
a nonparametric estimator of this quantity that respects the fact that this
is a multiple sample problem and enables the use of modern data adaptive
regression and density estimation techniques to estimate the underlying base-
line biomarker distribution, worst-case unvaccinated risk, and vaccine efficacy
lower bound.
The validity of our population level lower bound on the vaccine efficacy in
the new population relies on three main conditions. One of these conditions
essentially states that the support of the key biomarker in the new setting is
contained in that of the old efficacy trials so that it is possible to learn about
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the new setting from these trials. Another states that the results from the
earlier trials can be used to derive a lower bound of the conditional vaccine
efficacy curve in the new setting. A special case of this condition is that the
conditional vaccine efficacy curve is constant across trials. While these two
conditions alone allow one to get a lower bound on the marginal vaccine effi-
cacy, this lower bound can be very loose when the biomarker is truly a modifier
of vaccine efficacy because it involves finding the worst case distribution for the
conditional unvaccinated risk among the class of all such possible conditional
risk distributions. We thus add a third condition, namely that the marginal
unvaccinated risk is equal to a user-specified constant µ. Adding this con-
straint can greatly tighten the lower bound. The user can then report lower
confidence bounds resulting from our procedure at a range of plausible values
of µ.
In this work, we have assumed that one is able to define a lower bound on
the vaccine efficacy conditional only on baseline covariates and not on (coun-
terfactual) post-vaccination immune responses. There are advantages and dis-
advantages to this problem setup. The advantage is that, if the lower bound
assumption is valid, investigators can partially bridge the vaccine efficacy to
a new setting without vaccinating any individuals in the new population and
subsequently waiting to measure the immune response. Avoiding running a
phase I immunogenicity trial can save significant financial resources and can
also accelerate the introduction of a potentially life-saving vaccine into the new
population. The disadvantage of bridging using only using baseline covariates
is that the post-vaccination immune response is often more strongly associ-
ated with vaccine efficacy, and so a partial bridging assumption that accounts
for these responses may be more plausible or less conservative. Gilbert and
Huang (2016) consider bridging within a principal stratification framework,
thereby allowing for conditioning on counterfactual immune responses. In a
future work, we will present a doubly robust partial bridging procedure that
allows for conditioning on post-vaccination biomarkers.
Our vaccine efficacy lower bound depends on the marginal unvaccinated
risk level µ. While in many settings subject-matter experts may be able to
suggest a plausible range of values for µ, in other cases there may not be suffi-
cient knowledge of the marginal risk for this to be possible. To deal with this
issue, one could follow the suggestion of Gilbert and Huang (2016) to formally
incorporate epidemiologic surveillance data to learn such a range. While there
may not be biomarker and baseline risk information jointly available, one may
at times have reasonably accurate active surveillance data available to esti-
mate the marginal unvaccinated risk in the new population. In this case, one
could estimate our µ parameter rather than report a range of plausible values.
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One could then either treat this estimate as the truth, or modify our inferen-
tial procedure to incorporate the added uncertainty. While active surveillance
data should be incorporated when it exists, often only data from national
surveillance systems is available. These data may not be sufficiently accurate
to inform plausible values of µ. For example, recent studies of national surveil-
lance of dengue incidence have shown up to 19-fold underreporting compared
to active surveillance (Nealon et al., 2016; Sarti et al., 2016).
The results in this paper readily extend to a large class of contrasts f(µ1, µ0)
between the marginal vaccinated risk µ1 and unvaccinated risk µ0. We have
studied the multiplicative efficacy f(µ1, µ0) = 1 − µ1/µ0. If one is willing
to make the three bridging assumptions made in this paper, namely a sup-
port condition, lower bounded conditional multiplicative vaccine efficacy, and
specified unvaccinated risk, then obtaining a lower bound for more general
f(µ1, µ0) is straightforward. Suppose that, for each µ0, f(µ1, µ0) is sufficiently
smooth and monotonically decreasing in µ1 (the higher the risk among vacci-
nated individuals, the lower the efficacy). For a user-defined µ, one can then
conservatively estimate f(µ1, µ) by upper bounding µ1, which is indeed what
we do in Section 2. When µ = µ0, one then gets a lower bound for the efficacy
parameter of interest. All typical contrasts, including additive and odds-ratio
type contrasts, appear to satisfy this monotonicity condition.
Finally, we note that, while we have focused our discussion on the inter-
vention A being a vaccination indicator, the results given in this paper apply
immediately to any binary intervention A and multiplicative efficacy parame-
ter.
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Appendix
A Additional regularity conditions for Theo-
rem 3
For general P ′ ∈ M, below we write VE′− and D′VE,s for the analogues of
w 7→ VE0−(w) and D0VE,s under P ′ rather than P0. Define
Rem1(P ′,P0)(w)
,
S∑
s=1
∣∣∣∣E′s[Y |A = 0, w]− E0s[Y |A = 0, w] + E0s [ 1{A=0}P ′s(A|w) (Y − E0s[Y |A,w])
∣∣∣∣w]∣∣∣∣
=
S∑
s=1
∣∣∣∣(1− P 0s (A = 0|w)P ′s(A = 0|w)
)(
E′s[Y |A = 0, w]− E0s[Y |A = 0, w]
)∣∣∣∣ ,
Rem2(P ′,P0)(w)
, c(w)− VE0−(w) +
S∑
s=1
E0s
[
D′VE,s(O)
∣∣w]
=
[
VE′−(w)− VE0−(w)
] [
1− v0(w)d(0, w) +
∑S
s=1 vs(w)E
0
s [Y |A = 0, w]
v0(w)d(0, w) +
∑S
s=1 vs(w)E
′
s [Y |A = 0, w]
]
−
VE′−(w)
∑
s vs(w)
[
1− P 0s (A=0|w)
P ′s(A=0|w)
] (
E′s[Y |A = 0, w]− E0s[Y |A = 0, w]
)
v0(w)d(0, w) +
∑S
s=1 vs(w)E
0
s [Y |A = 0, w]
.
We now state the additional regularity conditions needed for Theorem 3.
C2) Pn is consistent in the sense that all of the following terms are oP (n−1/2min ):∥∥Rem1(Pn,P0)∥∥2,P 0? ,∥∥Rem2(Pn,P0)∥∥2,P 0? .
Furthermore, for each s = 1, . . . , S, all of the following terms are also
oP (n
−1/2
min ):
sup
β:W→[0,1]
∥∥∥w 7→ E0s[Dβ,nUR,s|w]− E0s[Dβ,0UR,s|w]∥∥∥
2,P 0s
∥∥∥∥dP n?dP ns − dP
0
?
dP 0s
∥∥∥∥
2,P 0s
,∥∥∥∥dP n?dP ns − dP
0
?
dP 0s
∥∥∥∥
2,P 0s
sup
β:W→[0,1]
∥∥∥w 7→ E0s[Dβ,nUR,s(O)|w]− E0s[Dβ,0UR,s(O)|w]∥∥∥
2,P 0s
,
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∥∥∥∥dP n?dP ns − dP
0
?
dP 0s
∥∥∥∥
2,P 0s
∥∥w 7→ E0s[DnVE,s(O)|w]− E0s[D0VE,s(O)|w]∥∥2,P 0s ,∥∥υn − υ0∥∥
2,P 0s
∥∥VEn−VE0−∥∥2,P 0s .
Like Donsker conditions used in one-sample problems, C3 requires certain
centered and scaled empirical means to be tight random elements. The next
assumption makes this requirement formal.
C3) (Qns − P 0s )∇Ωβ0,ns = OP (n−1/2min ), (Qns − P 0s )∇Ωβ̂n,ns = OP (n−1/2min ) for each
s ∈ S.
In our multiple sample problem, one can analyze (Qns − P 0s )∇Ωβ,ns for β fixed
(β = β0) or random (β = β̂n) for each s by conditioning on all observations not
belonging to trial s, and then applying a maximal inequality (which relies on
the bracketing or uniform entropy integral of the class to which ∇Ωβ,ns belongs,
see van der Vaart and Wellner, 1996) to bound the randomness in this term
resulting from observations in trial s.
We also require a condition that is similar to asymptotic equicontinuity
conditions implied by the use of Donsker classes in one-sample problems.
C4) (Qns −P 0s )[∇Ωβ̂n,ns −∇Ωβ0,0s ], (Qns −P 0s )[∇Γβ̂n,ns −∇Γβ0,0s ] for each s ∈ S.
Using the same arguments outlined following C3, one can show that, if ∇Ωβ̂n,ns
and ∇Γβ̂n,ns respectively converge to ∇Ωβ0,0s and ∇Γβ0,0s in P 0s mean-square, we
will allow be able to establish C4. While we do not formally give conditions
under which this mean-square convergence occurs, the primary assumption
needed in addition to the consistency conditions used in C2 is that θ̂n is consis-
tent for θ0. We give sufficient conditions for this convergence in Lemma A.14.
The next assumption is made for simplicity, though it is very mild, espe-
cially under B4, which states that w 7→ VE0−(w) is bounded away from −∞.
C5) infw VE
n(w) > −c > −∞ with probability approaching one, where the
constant c <∞ does not depend on sample size.
We make two additional assumptions when C1 holds. We first assume that
the empirical version of ωβ
0,0 is also close to µ, which seems reasonable given
that ωβ
0,0 = µ under C1.
C6) ω̂β̂
n,n − µ = oP (n−1/2min ).
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This condition can formally be supported in practice by looking at the size of
ω̂β̂
n,n− µ. The next regularity condition ensures that β̂n is a sufficiently good
estimate of β0 so that URβ̂
n,0 can be interpreted as being approximately equal
to the the worst-case conditional unvaccinated risk.
C7) Remn3 , γβ̂
n,0 − γβ0,0 − θ0[ωβ̂n,0 − ωβ0,0] = oP (n−1/2min ).
We give more interpretable sufficient conditions for C7 in Appendix C. These
conditions are a variant of the margin assumptions used in the classification
literature.
B Proofs
B.1 Proof of lower bound
Proof of Lemma 1. Because µ = E0?[E
0,F
? [Y |A = 0,W ]] and B2 holds, ωβ0,0 =
µ. By B1, ωβ
0,0Ψ(P 0,F? ) ≥ E0?[E0,F? [Y |A = 0,W ] VE0−(W )]. Below we respec-
tively use E1, E2, and E3 to denote the events {VE0−(W ) < θ0}, {VE0−(W ) = θ0},
and {VE0−(W ) > θ0}, we see that
ωβ
0,0Ψ(P 0,F? )− γβ
0,0 ≥ E0?[E0,F? [Y |A = 0,W ] VE0−(W )]− γβ
0,0
= E0?
[
(1E1 +η
0 1E2)
{
E0,F? [Y |A = 0,W ]− υ0(W )
}
VE0−(W )
]
+ E0?
[
(1E3 +[1− η0]1E2)
{
E0,F? [Y |A = 0,W ]− λ0(W )
}
VE0−(W )
]
.
By B2 and the fact that η0 ∈ [0, 1], replacing each instance of VE0−(W ) on
the right-hand side by θ0 yields a lower bound of the form θ0
[
µ− ωβ0,0
]
. As
ωβ
0,0 = µ, this lower bound is equal to zero. Dividing both sides by ωβ
0,0 > 0
gives the result.
Lemma A.1. If λ0 ≡ 0, B3, and B4, then φ0µ is monotonically nondecreasing
in µ.
Proof of Lemma A.1. Fix θ1 ≤ θ2 and x1, x2 ∈ [0, 1]. If θ1 = θ2, then suppose
also that x1 ≤ x2. For k = 1, 2, define βk , w 7→ 1{VE0−(w)<θk}+xk 1{VE0−(w)=θk}.
Note that β2(w) − β1(w) ≥ 0 and is strictly positive only if VE0−(W ) ≥ θ1.
Observe that
γβ1,0
ωβ1,0
− γ
β2,0
ωβ2,0
=
[
ωβ2,0 − ωβ1,0] γβ1,0 − ωβ1,0 [γβ2,0 − γβ1,0]
ωβ1,0ωβ2,0
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=
E0?
[{β2(W )− β1(W )}υ0(W ){γβ1,0 − VE0−(W )ωβ1,0}]
ωβ1,0ωβ2,0
≤ E
0
? [{β2(W )− β1(W )}υ0(W )]
[
γβ1,0 − θ1ωβ1,0
]
ωβ1,0ωβ2,0
.
Noting that
γβ1,0 = E0?[υ0(W ){1{VE0−(w)<θ1}+x1 1{VE0−(w)=θ1}}VE
0−(W )]
≤ θ1 E0?[υ0(W ){1{VE0−(w)<θ1}+x1 1{VE0−(w)=θ1}}] = θ1ω
β1,0,
we see that γ
β1,0
ωβ1,0
≤ γβ2,0
ωβ2,0
.
We now write θ0µ and x
0
µ to make the dependence of θ
0, η0 on µ explicit. As
υ0(w) > 0 for all w, clearly µ1 < µ2 implies that θ
0
µ1
≤ θ0µ2 and, if θ0µ1 = θ0µ2 ,
then also that x0µ1 ≤ x0µ2 . This completes the proof.
B.2 Pathwise derivative of Φ (Theorem 2)
Throughout this section, we refer to parameters evaluated at the collection
of distributions P rather than parameters evaluated at P0 by replacing the
superscript zero by superscript , e.g. we write υ , Υ(P) rather than υ0 ,
Υ(P0).
We now prove Theorem 2. The proof references results that we prove later
in this section.
Proof of Theorem 2. We consider the cases that C1 holds and that C1’ holds
separately. The proof in the case where C1” holds is nearly identical that
under C1’, and so the proof is omitted.
Case 1: C1 holds. By C1 and the fact that υ0 is bounded away from zero,
ωβ
0,0 = µ and θ0 is finite. By Lemma A.6, θ is finite for all  small enough so
that ωβ
, = µ for these . Hence, φ−φ0 = γβ
,−γβ0,0
µ
for all  sufficiently small.
Dividing both sides by , taking the limit as → 0, and applying Theorem A.3
(Section B.2.2) shows that the gradients of Φ at P0 are given by the desired
expressions.
Case 2: C1’ holds. The key to proving Theorem 2 under C1’ is proving that
P ?{VE−(W ) < θ} = P 0? {VE0−(W ) < θ0} = 1 for all  small enough. We
formally prove this in Lemma A.2 (Section B.2.1). It follows that
Φ(P)− Φ(P0) = E

? [υ
(W ) VE(W )]
E? [υ(W )]
− E
0
?
[
υ0(W ) VE0−(W )
]
E0? [υ0(W )]
.
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Dividing both sides by  and taking the limit as  → 0 yields the same
expression that would be used to evaluate the gradients of the parameter
P ′ →
∫
Υ(P ′)(w) VE′−(w)dP ′?(w)∫
Υ(P ′)(w)dP ′?(w) . It is straightforward to derive expressions for the
gradients of this parameter via the delta method.
B.2.1 Lemma used to Prove Theorem 2 under C1’.
Lemma A.2. If B3, B4, and C1’, then P ?{VE−(W ) < θ} = 1 for all  small
enough.
Proof of Lemma A.2. Standard pathwise differentiability calculations show that
E?[υ(W )]− ωβ0,0

=
E?[υ(W )]− E0?[υ0(W )]

=
∑
s∈S
P s∇Ωβ
0,0
s + o(1),
and the fact that each ∇Ωβ0,0s (Os) has mean zero for Os ∼ P 0s implies that the
right-hand side is O(1). By C1’, ωβ
0,0 < µ. Hence, E?[υ(W )] < µ + O(). It
follows that, for all  sufficiently small, E?[UR
w 7→1{VE−(w)<θ},(W )] < µ for all
θ. Hence, θ = +∞ for all  sufficiently small, completing the proof.
B.2.2 Theorem used to prove Theorem 2 under C1. The follow-
ing theorem establishes the pathwise differentiability of the parameter P ′ 7→
Γβ
′
(P ′), where the β′ in the subscript is the analogue of β0 but defined at
parameter input P ′ rather than at P0.
Theorem A.3. If B3, B4, and C1, then P ′ 7→ Γβ′(P ′) is pathwise differen-
tiable at P0 with P 0s gradients os 7→ ∇Γβ0,0s (os)− θ0∇Ωβ0,0s (os), s ∈ S.
Proof of Theorem A.3. Observe that
γβ
, − γβ0,0

=
γβ
0, − γβ0,0

+
γβ
, − γβ0,

.
We wish to obtain an expression for the limit on the left as → 0. If the limits
exist for both terms on the right, then the limit on the left is given by their
sum. A standard delta method argument shows that the limit as → 0 on the
right is given by
∑
s∈S P
0
s∇Γβ0,0s hs. Lemma A.4 shows that the limit exists for
the latter term and provides its closed form expression.
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Lemma A.4. Under the conditions of Theorem A.3,
lim
→0
γβ
, − γβ0,

= −θ0
∑
s∈S
∫
∇Ωβ0,0s (os)hs(os)dP 0s (os).
Proof of Lemma A.4. Telescoping yields that
γβ
, − γβ0, = E?
[{
URβ
,(W )− URβ0,(W )
}
VE(W )
]
= E?
[{
URβ
,(W )− URβ0,(W )
}{
VE(W )− θ0}]
+ θ0
∫ {
URβ
,(w)dP ?(w)− URβ
0,0(w)dP 0? (w)
}
− θ0
∫ {
URβ
0,(w)dP ?(w)− URβ
0,0(w)dP 0? (w)
}
.
We denote the first and second terms in the final equality by T 1 and T

2 . If
we can show that T 1 and T

2 are o(), then the result is immediate by dividing
both sides by  and applying the chain rule to the third term.
The remainder of this proof uses a positive constant c that may vary line
by line. We first establish that T 1 = o(). Straightforward calculations show
that
|T 1 | ≤ (1 + c||)E0?
[{∣∣∣URβ,0(W )− URβ0,0(W )∣∣∣+ c||}
× {∣∣VE0−(W )− θ0∣∣+ c||}
]
.
For simplicity we suppose that η = 0 for the remainder of the proof, but the
proof with η 6= 0 is nearly identical. For each w,∣∣∣URβ,0(w)− URβ0,0(w)∣∣∣ = ∣∣∣∣1{VE−(w)<θ}−1{VE0−(w)<θ0}
∣∣∣∣ [υ0(w)− λ0(w)].
Using that 1{VE−(w)<θ} 6= 1{VE0−(w)<θ0} implies that 0 ≤ |VE
0−(w) − θ0| <
|VE−(w)− θ − VE0−(w) + θ0| then shows that
|T 1 | ≤ (1 + c||)E0?
∣∣∣∣∣1{0≤|VE0−(w)−θ0|<|VE−(w)−θ−VE0−(w)+θ0|}
× {[υ0(W )− λ0(W )]|VE0−(W )− θ0|+ c||}
∣∣∣∣∣.
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The indicator above can be replaced by 1{0<|VE0−(w)−θ0|<|VE−(w)−θ−VE0−(w)+θ0|}
because C1 implies that P 0? (VE
0−(W ) = θ0) = 0. Combining this with the fact
that υ0(W )− λ0(W ) ≤ 1 and |VE−(w)− VE0−(w)| ≤ c|| shows that
|T 1 | ≤ (1 + c||)E0?
[
1{0<|VE0−(w)−θ0|<|VE−(w)−θ−VE0−(w)+θ0|}
{|θ − θ0|+ c||}] .
By Lemma A.6, θ − θ0 = O() so that, for all  large enough,
|T 1 | ≤ c||P 0?
{
0 < |VE0−(w)− θ0| < c||
}
.
The probability statement is o(1). Thus, T 1 = o().
Lemma A.6 establishes that θ is finite for all  small enough, and
The assumption that C1 establishes that θ0 is finite, and thus Lemma A.6
establishes that θ is finite for all  small enough. It follows that ωβ
, = µ for
all  small enough, and thus T 2 = ω
β, − ωβ0,0 = 0 for these .
Lemma A.5. For each t, let β˜t , w 7→ 1{VE0−(w)<t}. If C1 holds, then, for all
θ in a neighborhood of θ0,
0 < lim inf
t→0
ωβ˜θ+t,0 − ωβ˜θ,0
t
≤ lim sup
t→0
ωβ˜θ+t,0 − ωβ˜θ,0
t
<∞,
Proof of Lemma A.5. As υ0(w) − λ0(w) ≥ δ for all w, the facts that t 7→
P 0? {VE0−(W ) < θ0 + t} is monotonically non-decreasing and that C1 holds
yield that
lim inf
t→0
ωβ˜θ+t,0 − ωβ˜θ,0
t
= lim inf
t→0
E0?[{υ0(W )− λ0(W )}I{θ0 ≤ VE0−(W ) < θ0 + t}]
t
≥ δ lim inf
t→0
P 0? {VE0−(W ) < θ0 + t} − P 0? {VE0−(W ) < θ0}
t
> 0.
The limit supremum result is proven similarly.
Lemma A.6. Under the conditions of Theorem A.3, θ = θ0 +O().
Proof of Lemma A.6. In what follows we abuse notation and write ωθ, for
ω
w 7→1{VE−(w)<θ}, for all θ, . Note that, by C1, η0 = 0 so that ωβ0,0 = ωθ0,0.
We similarly abuse notation by letting URθ, , UR
w 7→1{VE−(w)<θ}, and Dθ,UR,s ,
D
w 7→1{VE−(w)<θ},
UR,s .
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We first establish that θ → θ0. For t > 0, the definition of θ yields that
|θ − θ0| > t implies that either ωθ0−t, > µ or ωθ0+t, ≤ µ. We will establish
that θ → θ0 by showing that, for any t > 0, both (i) ωθ0−t, ≤ µ and (ii)
ωθ
0+t, > µ, and therefore |θ − θ0| ≤ t.
For a constant c > 0 that may vary line by line,
ωθ
0−t, ≤ (1 + c||)E0?
[
URθ
0−t,(W )
]
= (1 + c||)E0?
[
λ(W ) + {υ(W )− λ(W )}1{VE−(W ) < θ0 − t}
]
≤ (1 + c||)E0?
[
λ(W ) + {υ(W )− λ(W )}1{VE0−(W ) < θ0 − t+ c||}
]
= (1 + c||)ωθ0−t+c||,0 + c||.
Now, we know that ωθ
0−t+c||,0 ≤ µ by the definition of the supremum, and
by C1 the inequality is strict. It follows that ωθ
0−t, < µ + c||(1 + µ), and
so ωθ
0−t, < µ for all || sufficiently small. Thus (i) holds. We now establish
(ii). Similarly to the above, we have that ωθ
0+t, ≥ (1 − c||)ωθ0+t−c||,0 − c||
for a constant c > 0. By the definition of the supremum, ωθ
0+t−c||,0 > µ for
all || sufficiently small. Thus, (ii) holds for all || sufficiently small. From
the observation at the beginning of the proof, the fact that (i) and (ii) hold
for all || sufficiently small implies that lim sup→0 |θ − θ0| ≤ t, and as t was
arbitrary this implies that θ − θ0 = o(1).
We now establish that θ − θ0 = O(). Using similar techniques to those
used above, one can show that there exists a c > 0 such that, for all θ,
(1− c||)ωθ−c||,0 − c|| ≤ ωθ, ≤ (1 + c||)ωθ+c||,0 + c||. (A.1)
Noting that µ ≥ ωθ,, we have that
0 ≥ ωθ, − ωθ0,0 ≥ (1− c||)ωθ−c||,0 − c|| − ωθ0,0
= (1− c||)
[
ωθ
−c||,0 − ωθ0,0
]
− c||(1 + ωθ0,0).
As C1 implies lim inft→0 ω
θ0+t,0−ωθ0,0
t
> 0 by Lemma A.5, B , lim inf→0B ,
lim inf→0 ω
θ−c||,0−ωθ0,0
θ−θ0−c|| is greater than zero. The above implies that, for all 
small enough,
c||(1 + ωθ0,0)
1− c|| ≥ ω
θ−c||,0 − ωθ0,0 = (θ − θ0 − c||)B.
Dividing both sides by B and taking the limit supremum of the left-hand side
as → 0 shows that θ − θ0 ≤ O().
The proof of the fact that θ − θ0 ≥ O() is analogous, making use of the
upper bound in (A.1) and the fact that µ < ωθ
+c||, if θ is finite (guaranteed
for all  small enough).
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B.3 Asymptotic linearity (Theorem 3)
In what follows, we write C1/C6/C7 to mean that C1, C6, and C7 hold. The
proof under C1” is essentially equivalent to that under C1’, so for simplicity
we only give the proof under C1’ and C1/C6/C7. Outside of formal theorem
statements, when we write that C1/C6/C7 holds or that C1’ holds, we mean
that the stated condition(s) and the other conditions of Theorem 3, namely
B3, B4, C2, C3, C4, and C5, hold.
We prove Theorem 3 by analyzing the terms on the right-hand side of the
following decomposition, whose derivation is straightforward:
φ̂n − φ0 = γ̂
β̂n,n
ω̂β̂n,n
− γ
β0,0
ωβ0,0
=
γ̂β̂
n,n − γβ̂n,0
ωβ0,0
− γ
β0,0
[ωβ0,0]2
[
ω̂β̂
n,n − ωβ0,0
]
+
γβ̂
n,0 − γβ0,0
ωβ0,0
+
[
γ̂β̂
n,n − γβ0,0
] [ 1
ω̂β̂n,n
− 1
ωβ0,0
]
+
γβ
0,0
ω̂β̂n,n[ωβ0,0]2
[
ω̂β̂
n,n − ωβ0,0
]2
,Term 1− Term 2 + Term 3 + Term 4 + Term 5. (A.2)
We will show that Term 1 is non-negligible, i.e. contributes to the dominant
OP (n
−1/2
min ) term in the asymptotically linear expansion, under both C1/C6/C7
and C1’, Term 2 is negligible, i.e. oP (n
−1/2
min ), under C1/C6/C7 and non-
negligible under C1’, and Term 3 is non-negligible under C1/C6/C7 and neg-
ligible under C1’. Terms 4 and 5 are remainder terms that one can ignore
if they invoke the delta method. Indeed, if we show that ω̂β̂
n,n − ωβ0,0 and
γ̂β̂
n,n−γβ0,0 are OP (n−1/2min ), then Terms 4 and 5 are negligible. As this is what
we will show under both C1/C6/C7 and C1’, Terms 4 and 5 can be shown to
be negligible by our analysis of the first three terms.
The following theorem establishes the behavior of Term 1 by studying
γ̂β̂
n,n − γβ̂n,0.
Theorem A.7 (Term 1). If B4, C2, C4, and C5, then
γ̂β̂
n,n − γβ̂n,0 =
∑
s∈S
(Qns − P 0s )∇Γβ
0,0
s + oP (n
−1/2
min ).
The proof of Theorem A.7 is given in Appendix B.3.1.
The fact that Term 2 is negligible under C1/C6/C7 is an immediate con-
sequence of C6. We now present a theorem that establishes the behavior of
Term 3 under C1/C6/C7.
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Theorem A.8 (Term 3 under C1/C6/C7). If B4, C1, C2, C4, C6, and C7,
then
γβ̂
n,0 − γβ0,0 = −θ0
∑
s∈S
(Qns − P 0s )∇Ωβ
0,0
s + oP (n
−1/2
min ).
The proof of Theorem A.8 is given in Appendix B.3.2.
We now present a lemma and a theorem that respectively establish the be-
havior of Terms 3 and 2 under C1’. Both results are proven in Appendix B.3.3.
Lemma A.9 (Term 3 under C1’). If B4, C1’, C2, and C3, then θ̂n = +∞,
and consequently Qn?{VEn−(W ) < θ̂n} = 1, with probability approaching one.
The proof of Lemma A.9 is given in Appendix B.3.3. By C1’, θ0 = +∞,
so that the above shows that θ̂n = θ0, and thus that Term 2 is zero, with
probability approaching one.
Theorem A.10 (Term 2 under C1’). If B4, C1’, C2, and C4, then
ω̂β̂
n,n − ωβ0,0 =
∑
s∈S
(Qns − P 0s )∇Ωβ
0,0
s + oP (n
−1/2
min ).
The proof of Theorem A.10 is given in Appendix B.3.3.
B.3.1 Term 1 under C1/C6/C7 and C1’. We give a lemma before
proving Theorem A.7.
Lemma A.11. Under the conditions of Theorem A.7,
γβ̂
n,n − γβ̂n,0 +
∑
s∈S
P 0s∇Γβ̂
n,n
s = oP (n
−1/2
min ).
Proof of Lemma A.11. Note that
γβ̂
n,n − γβ̂n,0 +
∑
s∈S
P 0s∇Γβ̂
n,n
s
= E0?
[
URβ̂
n,n(W ) VEn(W )
]
− γβ̂n,0 +
S∑
s=1
P 0s∇Γβ̂
n,n
s . (A.3)
Furthermore,
S∑
s=1
P 0s∇Γβ̂
n,n
s
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=
S∑
s=1
E0s
[
dP n?
dP ns
(W )
{
Dβ̂
n,n
UR,s(O) VE
n(W ) + URβ̂
n,n(W )DnVE,s(O)
]]
= E0?
[
S∑
s=1
{
Dβ̂
n,n
UR,s(O) VE
n(W ) + URβ̂
n,n(W )DnVE,s(O)
}]
(A.4)
+
S∑
s=1
E0s
[{
dP n?
dP ns
(W )− dP
0
?
dP 0s
(W )
}{
Dβ̂
n,n
UR,s(O) VE
n(W ) + URβ̂
n,n(W )DnVE,s(O)
}]
.
The law of total expectation and the fact that Dβ̂
n,0
UR,s and D
0
VE,s are mean zero
when applied to a random variable Os drawn from the conditional distribution
Os|W under P 0s yield that the latter line is bounded above by
S∑
s=1
E0s
[{
dP n?
dP ns
(W )− dP
0
?
dP 0s
(W )
}
×
{(
E0s[D
β̂n,n
UR,s(O)|W ]− E0s[Dβ̂
n,0
UR,s(O)|W ]
)
VEn(W )
+ URβ̂
n,n(W )
(
E0s[DnVE,s(O)|W ]− E0s[D0VE,s(O)|W ]
)}]
.
The above is oP (n
−1/2
min ) by Cauchy-Schwarz, C2, C5, and the fact that UR
β̂n,n,
VEn have bounded range. Furthermore, (A.4) simplifies to
E0?
[
S∑
s=1
{
Dβ̂
n,n
UR,s(O) VE
n(W ) + URβ̂
n,n(W )DnVE,s(O)
}]
= E0?
[{
[URβ̂
n,0(W )− URβ̂n,n(W )] VEn(W ) + URβ̂n,n(W )[VE0−(W )− VEn(W )]
}]
+ E0?
[{
URβ̂
n,n(W )− URβ̂n,0(W ) +
S∑
s=1
Dβ̂
n,n
UR,s(O)
}
VEn(W )
]
+ E0?
[
URβ̂
n,n(W ) Rem2(Pn,P0)
]
.
The final line is oP (n
−1/2
min ) by C2. The magnitude of the second line is upper
bounded by E0? [Rem1(Pn,P0)(W )|VEn(W )|], which is also oP (n−1/2min ) by C2.
We have thus established that (A.3) rewrites as
γβ̂
n,n − γβ̂n,0 +
∑
s∈S
P 0s∇Γβ̂
n,n
s
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= E0?
[
{URβ̂n,n(W )− URβ̂n,0(W )}{VE0−(W )− VEn(W )}
]
+ oP (n
−1/2
min ).
By Cauchy-Schwarz and C2, the leading term on the right is oP (n
−1/2
min ), so that
indeed the entire right-hand side is oP (n
−1/2
min ).
We now prove Theorem A.7.
Proof of Theorem A.7. Rearranging the result of Lemma A.11 yields that
γβ̂
n,n − γβ̂n,0 = −
∑
s∈S
P 0s∇Γβ̂
n,n
s + oP (n
−1/2
min ).
Adding
∑
s∈S Q
n
s∇Γβ̂n,ns to both sides shows that the one-step estimator γ̂β̂n,n
satisfies the identity
γ̂β̂
n,n − γβ̂n,0 =
∑
s∈S
(Qns − P 0s )∇Γβ̂
n,n
s + oP (n
−1/2
min ).
Applying C4 allows one to replace each instance of ∇Γβ̂n,ns above by ∇Γβ0,0s ,
s ∈ S.
B.3.2 Term 3 under C1/C6/C7. We first give two lemmas, and then we
establish control of Term 3 by proving Theorem A.8.
Lemma A.12. If B4 and C2, then∣∣∣∣∣ω̂β̂n,n − ωβ̂n,0 −∑
s∈S
(Qns − P 0s )∇Ωβ̂
n,n
s
∣∣∣∣∣ = oP (n−1/2min ).
Proof of Lemma A.12. Note that
ωβ̂
n,n +
∑
s∈S
P 0s∇Ωβ̂
n,n
s
= E0?
[
URβ̂
n,n(W )
]
+
S∑
s=1
E0s
[
dP n?
dP ns
(W )Dβ̂
n,n
UR,s(O)
]
=ωβ̂
n,0 + E0?
[
URβ̂
n,n(W )− URβ̂n,0(W ) +
S∑
s=1
E0s
[
Dβ̂
n,n
UR,s(O)
∣∣∣W]]
+
S∑
s=1
E0s
[{
dP n?
dP ns
(W )− dP
0
?
dP 0s
(W )
}{
E0s
[
Dβ̂
n,n
UR,s(O)
∣∣∣W]− E0s [Dβ̂n,0UR,s(O)∣∣∣W]}] ,
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where the final equality uses that E0s
[
Dβ̂
n,0
UR,s(O)
∣∣∣W] = 0. The second line is
oP (n
−1/2
min ) by C2 and Cauchy-Schwarz. The triangle inequality readily yields
that
E0?
∣∣∣∣∣URβ̂n,n(W )− URβ̂n,0(W ) +
S∑
s=1
E0s
[
Dβ̂
n,n
UR,s(O)
∣∣∣W]∣∣∣∣∣ ≤ E0? ∣∣Rem1(Pn,P0)(W )∣∣ ,
and the right-hand side is oP (n
−1/2
min ) by C2. The fact that ω̂
β̂n,n , ωβ̂n,n +∑
s∈S Q
n
s∇Ωβ̂n,ns completes the proof.
Proof of Theorem A.8. Note that
γβ̂
n,0 − γβ0,0 =E0?
[{
URβ̂
n,0(W )− URβ0,0(W )
}
VE0−(W )
]
=θ0
[
ωβ̂
n,0 − ωβ0,0
]
+
{
γβ̂
n,0 − γβ0,0 − θ0
[
ωβ̂
n,0 − ωβ0,0
]}
.
By C7, the latter term above is oP (n
−1/2
min ). By Lemma A.12 and C6,
ωβ̂
n,0 = ωβ̂
n,n +
∑
s∈S
Qns∇Ωβ̂
n,n
s −
∑
s∈S
(Qns − P 0s )∇Ωβ̂
n,0
s + oP (n
−1/2
min )
= µ−
∑
s∈S
(Qns − P 0s )∇Ωβ̂
n,0
s + oP (n
−1/2
min ).
By C1, ωβ
0,0 = µ, and so
θ0
[
ωβ̂
n,0 − ωβ0,0
]
= −θ0
∑
s∈S
(Qns − P 0s )∇Ωβ̂
n,0
s + oP (n
−1/2
min ).
By C4, we can replace each Ωβ̂
n,0
s above by Ω
β0,0
s .
B.3.3 Terms 2 and 3 under C1’. We first prove Lemma A.9, thereby
showing that Term 3 is equal to zero with probability approaching 1. We then
establish control over Term 2 by proving Theorem A.10.
Proof of Lemma A.9. By C1’, θ0 = +∞. We show that ω̂β0,n ≤ µ, and conse-
quently β̂n = +∞, with probability approaching one. Note that
ω̂β
0,n − ωβ0,0 =
∑
s∈S
(Qns − P 0s )∇Ωβ
0,n
s +
{
ω̂β
0,n − ωβ0,0 +
∑
s∈S
P 0s∇Ωβ
0,n
s
}
.
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The first term on the right is OP (n
−1/2
min ) by C3, and the latter term is oP (n
−1/2
min )
by C2. Hence, ω̂β
0,n = ωβ
0,0 + OP (n
−1/2
min ). By C1’, ω
β0,0 < µ, and thus
ω̂β
0,n < µ with probability approaching one. As β0 ≡ 1, it must be the case
that θ̂n = +∞.
Proof of Theorem A.10. By Lemma A.9, θ̂n = +∞ with probability approach-
ing 1. Suppose this holds. In this case the TMLE step ensures that ω̂β̂
n,n =
Qn?υ
n. Furthermore, C1’ implies that ωβ
0,0 = P 0? υ
0. By the definition of Rem1,
we have that
ω̂β̂
n,n − ωβ0,0 = (Qn? − P 0? )υn + P 0? (υn − υ0)
= (Qn? − P 0? )∇Ωβ̂
n,n
? −
S∑
s=1
P 0?D
β̂n,n
UR,s + P
0
? Rem1(Pn,P0).
By C2, P 0? Rem1(Pn,P0) = oP (n−1/2min ). Furthermore,
S∑
s=1
P 0?D
β̂n,n
UR,s =
S∑
s=1
P 0s∇Ωβ̂
n,n
s +
S∑
s=1
P 0s
[
dP 0?
dP 0s
− dP
n
?
dP ns
]
Dβ̂
n,n
UR,s.
Using that each Dβ
0
UR,s(O) is mean zero for O ∼ P 0s (conditionally on w), the
Dβ̂
n,n
UR,s on the right-hand side above can be replaced by D
β̂n,n
UR,s−Dβ
0
UR,s, thereby
showing that the latter term above is oP (n
−1/2
min ) by C2. Hence,
ω̂β̂
n,n − ωβ0,0 = (Qn? − P 0? )∇Ωβ̂
n,n
? −
S∑
s=1
P 0s∇Ωβ̂
n,n
s + oP (n
−1/2
min ).
By Steps 2, 3, and 4 of our estimation procedure and the fact that θ̂n =
+∞,∑Ss=1Qns∇Ωβ̂n,ns = 0 (these steps represent a standard logistic fluctuation
submodel for a TMLE, see van der Laan and Rose, 2011). This shows that
ω̂β̂
n,n − ωβ0,0 = ∑s∈S(Q0s − P 0s )∇Ωβ̂n,ns + oP (n−1/2min ). By C4, it follows that
ω̂β̂
n,n − ωβ0,0 = ∑s∈S(Q0s − P 0s )∇Ωβ0,0s + oP (n−1/2min ).
C More interpretable condition for C7
We now provide a more interpretable sufficient condition for C7. First note
that Remn3 rewrites as
Remn3 = E
0
?
[{
URβ̂
n,0(W )− URβ0,0(W )
}{
VE0−(W )− θ0
}]
.
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The expression in the expectation above is small when either β̂n(W ) = β0(W )
or VE0−(W ) is close to θ0. This observation gives some hope that the above
expectation will be small when VEn− and θ̂n are good estimates of w 7→
VE0−(w) and θ0, because it will likely only be most difficult to correctly specify
1{VEn−(W )≥θ̂n} when VE
0−(W )− θ0 is small.
We now make this claim precise. The following margin condition is anal-
ogous to that used by Audibert and Tsybakov (2007) in the classification
context. In particular, for each α > 0 we define Condition α as follows:
P ?0
{
0 < |VE0−(W )− θ0| ≤ t
}
. tα for all t > 0.
The above states that VE0−(W ) does not place too much mass in the neighbor-
hood of the decision boundary θ0 that appears in the worst-case unvaccinated
risk URβ
0,0. The following theorem is an adaptation of Lemma 5.2 in Audibert
and Tsybakov (2007). A similar adaptation was given in Luedtke and van der
Laan (2016b).
Lemma A.13. If C1 and Condition α holds for a given α > 0, then
|Remn3 | .
∥∥∥(VEn−(W )− θ̂n)− (VE0−(W )− θ0)∥∥∥2(1+α)/(2+α)
2,P 0?
|Remn3 | .
∥∥∥(VEn−(W )− θ̂n)− (VE0−(W )− θ0)∥∥∥1+α∞,P 0? .
Shortly we will show that we will show that we can get a faster rate of
estimation on the univariate parameter θ̂n than on the infinite-dimensional
parameter w 7→ VE0−(w) when α ≥ 1. Hence, in this case the above allows
us to map our rate of convergence of w 7→ VE0−(w) into a rate of decay for
the remainder term Remn3 . Suppose that α = 1, which holds if w 7→ VE0−(w)
has bounded Lebesgue density in a neighborhood of θ0. The supremum norm
result in the above lemma suggests that VEn− −θ̂n converging to VE0− −θ0 at a
rate faster than n
−1/4
min will suffice to make Rem
n
3 negligible.
We close this section by showing the rate of estimation that we can obtain
on θ0 provided the following additional regularity condition is satisfied:
C8)
∥∥VEn− −VE0−∥∥2,P 0? = oP (1).
The above is very mild if C2 holds.
Lemma A.14. If B4, C1, C2, C3, C6, and C8, then θ̂n = θ0 + oP (1). If
Condition α also holds, then we have the stronger result that
θ̂n − θ0 = OP
(
n
−1/2
min +
∥∥VEn− −VE0−∥∥ 2αα+12,P 0?) .
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Suppose, as is typical, that
∥∥VEn− −VE0−∥∥2,P 0? shrinks slower than n−1/2min .
In this case, if α ≥ 1, then the above gives conditions under which θ̂n =
θ0 +OP (
∥∥VEn− −VE0−∥∥2,P 0? ), where the big-oh can be replaced by a little-oh if
α > 1.
Proof of Lemma A.14. By C6, Lemma A.12, and C3,
oP (n
−1/2
min ) = ω̂
β̂n,n − µ = ωβ̂n,0 − ωβ0,0 +OP (n−1/2min ).
Let βn,0 denote the function w 7→ 1{VE0−(w)<θ̂n}. The above shows that
ωβ
n,0,0 − ωβ0,0 = −[ωβ̂n,0 − ωβn,0,0] +OP (n−1/2min )
At the end of this proof, we show that ωβ̂
n,0 − ωβn,0,0 = oP (1) without us-
ing Condition α. For now suppose we have established this. By C1, θ 7→
ω
w 7→1{VE0−(w)<θ},0 is continuous and increasing at θ0 so that ωβn,0,0 − ωβ0,0 =
oP (1) is only possible if θ̂
n − θ0 = oP (1). If Condition α also holds, then we
will show at the end of this proof that ωβ̂
n,0−ωβn,0,0 = OP (
∥∥VEn− −VE0−∥∥ 2αα+12,P 0? ).
Noting that
ωβ
n,0,0 − ωβ0,0 = ω
βn,0,0 − ωβ0,0
θ̂n − θ0
[θ̂n − θ0],
we see that C1 and θ̂n − θ0 = oP (1) imply that θ̂n − θ0 = OP (ωβn,0,0 − ωβ0,0),
which we have shown to be OP (n
−1/2
min +
∥∥VEn− −VE0−∥∥ 2αα+12,P 0? ) under Condition α.
We now establish that ωβ̂
n,0 = ωβ
n,0,0 + oP (1) regardless of the validity of
Condition α, and that ωβ̂
n,0 = ωβ
n,0,0+OP (
∥∥VEn− −VE0−∥∥ 2αα+12,P 0? ) under Condition
α. For simplicity we give the proof when η̂n = 0, though the proof for general
η̂n ∈ [0, 1] only differs slightly. Observe that∣∣∣ωβ̂n,0 − ωβn,0,0∣∣∣
=
∣∣∣∣E0? [{υ0(W )− λ0(W )}{1{VEn−(W )<θ̂n}−1{VE0−(W )<θ̂n}
}]∣∣∣∣
≤ E0?
[∣∣∣∣1{VEn−(W )<θ̂n}−1{VE0−(W )<θ̂n}
∣∣∣∣]
≤ P 0?
{
0 ≤ |VE0−(W )− θ̂n| ≤ |VEn−(W )− VE0−(W )|
}
.
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For any t > 0, the inequality continues as
≤ P 0?
{
0 ≤ |VE0−(W )− θ̂n| ≤ t
}
+ P 0?
{|VEn−(W )− VE0−(W )| ≥ t}
≤ P 0?
{
0 ≤ |VE0−(W )− θ̂n| ≤ t
}
+
∥∥VEn− −VE0−∥∥22,P 0?
t2
.
By C1, P 0? {VE0−(W ) = θ̂n} = 0, so that the former term satisfies
lim
t↓0
P 0?
{
0 ≤ |VE0−(W )− θ̂n| ≤ t
}
= 0.
As
∥∥VEn− −VE0−∥∥2,P 0? = oP (1) by C8, one can choose a sequence {tn} and
plug it in for t in the preceding inequality for
∣∣∣ωβ̂n,0 − ωβn,0,0∣∣∣ to see that
this quantity is oP (1). If Condition α holds, then one can choose tn =∥∥VEn− −VE0−∥∥2/(α+1)2,P 0? , yielding the stronger result∣∣∣ωβ̂n,0 − ωβn,0,0∣∣∣ . ∥∥VEn− −VE0−∥∥ 2αα+12,P 0? .
D Alternative to Steps 2, 3, and 4 in our es-
timation scheme
We now present alternatives to Steps 2, 3, and 4, to be used when neither
(i) `s(w) is a constant multiple of us(w) nor (ii) `s ≡ 0 for all s holds. The
estimation scheme is identical to that presented in the main text besides the
modification of these three steps.
2’) Fit a bivariate logistic regression with outcome (ys[i] : s = 1, . . . , S; i = 1, . . . , ns),
covariates
(
1{as[i]=0} `s(w)
nsP
n,init
s (A=0|ws[i])
dPn,init?
dPn,inits
(ws[i]) : s = 1, . . . , S; i = 1, . . . , ns
)
and(
1{as[i]=0} us(w)
nsP
n,init
s (A=0|ws[i])
dPn,init?
dPn,inits
(ws[i]) : s = 1, . . . , S; i = 1, . . . , ns
)
, and fixed, subject-
level intercept
(
logit
(
En,inits [Y |A = 0, ws[i]]
)
: s = 1, . . . , S; i = 1, . . . , ns
)
.
Denote the fitted coefficient in front of the respective covariates by `n
and un.
3’) For each s = 1, . . . , S, let (a, w) 7→ En,ns [Y |a, w] denote the function
(a, w) 7→ logit−1
[
logit
(
En,inits [Y |a, w]
)
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+ `n
1{a=0} `s(w)
nsP
n,init
s (A = 0|w)
dP n,init?
dP n,inits
(w)
+ un
1{a=0} us(w)
nsP
n,init
s (A = 0|w)
dP n,init?
dP n,inits
(w)
]
.
4’) Let Pn = (P n? , P n1 , . . . , P ns ) denote any collection of distribution satis-
fying that, for all (a, w), Ens [Y |a, w] = En,ns [Y |a, w], P ns (A = 1|w) =
P n,inits (A = 1|w), and dP
n
?
dPns
(w) = dP
n,init
?
dPn,inits
(w).
E Extensions
E.1 Two-phase sampling
Suppose now that the data is collected via a two-phase sampling scheme in a
given trial s ∈ {1, . . . , S}. In particular, suppose that W is collected on only a
subset of participants, whereas (L,A, Y ) is collected on all participants, where
L is a biomarker or collection of biomarkers that may be predictive of W . It
is not essential that L happens temporally before A and Y . If no biomarker
L is observed, then one can set L = 0 for all participants. Let ∆ be an
indicator of the missingness of W . In this setting, the full data distribution
for trial s is (W,L,A, Y ) ∼ P 0,Fs , and the observed data structure for trial s
is given by Os , (∆W,∆, L, A, Y ) ∼ P 0,Fs . We suppose that W is missing at
random, in the sense that ∆ ⊥ W |(L,A, Y ) for each trial s, and further that
censoring mechanism, i.e. the probability that ∆ = 1 given each realization of
(L,A, Y ), is known. This ensures that P 0,Fs can be identified with P
0
s by the
G-computation formula Robins (1986). In particular, for any event E on Os,
we have that P 0,Fs {E} = E0s[P 0s {E|∆ = 1, L}].
A common sampling scheme that generates such data in vaccine efficacy
trials is a nested case-control sampling scheme (Breslow, 1996), where the
outcome W is observed on all cases (participants with Y = 1), and the outcome
W is only observed on a subset of controls (Y = 0). Often these sampling
schemes will take the form of an m:1 scheme, such that, for each case with W
observed, W is observed for m controls. While technically the indicator ∆ is
drawn without replacement for these m individuals, one can typically ignore
this dependence in the data with little impact on precision or coverage.
A simple modification of our procedure via inverse probability weighting
allows estimation of our efficacy lower bound φ0. For efficiency gains, we rec-
ommend estimating the censoring mechanism even though it is known (see
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Theorem 2.3 in van der Laan and Robins, 2003). While estimating the cen-
soring mechanism improves the precision of our estimator, it does not reduce
the width of our confidence intervals. This thus leads to a conservative in-
ferential procedure. The proof of correctness of this approach is beyond the
scope of this work, though closely follows the arguments given in Rose and
van der Laan (2011), with minor tweaks to account for the multiple sample
nature of the problem. Indeed, Steps 2, 3, and 4 constitute an IPCW-TMLE,
as presented in Rose and van der Laan (2011). For simplicity we only give
the algorithm for the case presented in Section 4.1.1 in the main text, namely
where either (i) the chosen `s(w) is a constant multiple of the chosen us(w),
where the multiple is independent of s and w, or (ii) the chosen `s ≡ 0 for all
s so that λ0 ≡ 0. The modification of Steps 2, 3, and 4 is analogous to the
modifications made to the algorithm in the main text given in Appendix D.
We start at Step 0 so that the other steps parallel those given for the algorithm
in the main text.
To emphasize the fact that many of the parameters below depend on the full
data structure (W,L,A, Y ) rather than the (censored) observed data structure
(∆W,∆, L, A, Y ), we replace the “0” in the superscript by “0, F” when the
parameter is defined for the full data distribution, e.g. we write λ0,F rather
than λ0. Similarly, we write λn,F rather than λn when denoting estimates of
parameters of the full data distribution. Finally, we note that below we denote
the observed value of L and ∆ for participant i from trial s by ls[i] and δs[i],
respectively.
0. Estimate each (l, a, y) 7→ P 0s {∆ = 1|l, a, y} using a completed trial s-
specific correctly specified parametric model. Standardize these esti-
mates by an appropriate constant so that, for each s = 1, . . . , S,
ns∑
i=1
δs[i]
P ns {∆ = 1|ls[i], as[i], ys[i]}
= ns.
Note: correct parametric model specification is possible in this context
due to the presumed knowledge (by experimental design) of the censoring
mechanism P 0s {∆ = 1|l, a, y}.
1. Let (a, w) 7→ En,F,inits [Y |a, w], w 7→ P n,F,inits (A = 1|w), and w 7→ dP
n,F,init
?
dPn,F,inits
(w)
represent estimates of (a, w) 7→ E0,Fs [Y |a, w], w 7→ P 0,Fs (A = 1|w), and
w 7→ dP 0?
dP 0,Fs
(w), respectively.
Note: Rose and van der Laan (2011) describe a weighted loss-based esti-
mation scheme that leverages the information in the biomarker L when
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estimating these quantities. This procedure makes use of the estimate
of the censoring mechanism from Step 0. Rose and van der Laan (2011)
also extend the super-learner of van der Laan et al. (2007) to two-phase
sampling designs.
2. Fit a weighted univariate logistic regression with weights(
∆
Pns {δs[i]=1|ls[i],as[i],ys[i]} : s = 1, . . . , S; i = 1, . . . , ns
)
, outcome
(ys[i] : s = 1, . . . , S; i = 1, . . . , ns), covariate(
1{as[i]=0} us(w)
nsP
n,F,init
s (A=0|ws[i])
dPn,F,init?
dPn,F,inits
(ws[i]) : s = 1, . . . , S; i = 1, . . . , ns
)
, fixed, subject-
level intercept
(
logit
(
En,F,inits [Y |A = 0, ws[i]]
)
: s = 1, . . . , S; i = 1, . . . , ns
)
.
Denote the fitted coefficient in front of the covariate by n.
3. For each s = 1, . . . , S, let (a, w) 7→ En,F,ns [Y |a, w] denote the function
(a, w) 7→ logit−1
[
logit
(
En,F,inits [Y |a, w]
)
+ n
1{a=0} us(w)
nsP
n,F,init
s (A = 0|w)
dP n,F,init?
dP n,F,inits
(w)
]
.
4. Let Pn,F = (P n? , P n,F1 , . . . , P n,Fs ) denote any collection of distribution
satisfying that, for all (a, w), En,Fs [Y |a, w] = En,F,ns [Y |a, w], P n,Fs (A =
1|w) = P n,F,inits (A = 1|w), and dP
n
?
dPn,Fs
(w) = dP
n,F,init
?
dPn,F,inits
(w). Furthermore, for
each completed trial s, let Qn,Fs denote the distribution that puts mass
proportional to δs[i]/(nsP
n
s {∆ = 1|ls[i], as[i], ys[i]}) at each observation
i = 1, . . . , ns, and zero mass elsewhere.
5. For each β : W → [0, 1], let ω̂β,n,F , ωβ,n,F +∑s∈S Qn,Fs ∇Ωβ,n,Fs , and
note that ω̂β,n,F rewrites as Qn,F? UR
β,n,F +
∑S
s=1 Q
n,F
s ∇Ωβ,n,Fs .
6. Let θ̂n,F , sup{θ : ω̂
w 7→1{VEn,F− (w)<θ}
,n,F
≤ µ}, where sup ∅ = −∞.
7. Let η̂n,F be any element of the set argminη∈[0,1]
(
ω̂βη ,n,F − µ)2, where
βη , w 7→ 1{VEn,F− (w)<θ̂n,F }+η 1{VEn,F− (w)=θ̂n,F }.
8. Let β̂n,F , βη̂n,F .
9. Estimate γβ̂
n,F ,0 with
γ̂β̂
n,F ,n,F , γβ̂n,F ,n,F +
∑
s∈S
Qn,Fs ∇Γβ̂
n,F ,n,F
s
= n−1?
n?∑
i=1
URβ̂
n,F ,n,F (w?[i]) VE
n,F (w?[i]) +
S∑
s=1
Qn,Fs ∇Γβ̂
n,F ,n,F
s .
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10. Estimate φ0 with φ̂n,F , γ̂β̂
n,F ,n,F
ω̂β̂
n,F ,n,F
.
For confidence interval construction, we note that similar conditions to those
used in 3 yield that our estimator is asymptotically linear, with the same
P 0? gradient as in the main text (though with the observed data parameters
for the completed trial distributions replaced by full data parameters) and,
for s = 1, . . . , S, P 0s gradients os 7→ δP 0s {∆=1|l,a,y}∇Φ
0
s(os), again replacing the
observed data parameters by the full data parameters in the definition of
∇Φ0s(os).
Remark 6. Consider a randomized trial where L precedes randomization
and A is independent of L conditional on W . In this case, it is straightfor-
ward to improve the efficiency of the above procedure if L is predictive of
Y after accounting for A and W in at least one of the trials. In particular,
efficiency could be improved by leveraging this biomarker when estimating
both the (known) propensity score P 0,Fs {A|W} and the outcome regression
E0,Fs [Y |A,W ], namely by adding L to the both of the corresponding condi-
tioning statements. The same efficiency gain of course holds for the algorithm
in the main text, since setting ∆ = 1 with probability one shows that W being
observed on all individuals is a special case of the results in this appendix. 2
E.2 Monotonic vaccine efficacy curve
In this section, we describe a situation in which one can replace the condition
that P 0? {VE0−(W ) = θ0} = 0 with the following new condition:
M) W is real-valued and w 7→ VE0−(w) is monotonic.
We break this section into three parts. First, we present a new partial
bridging formula specific to the monotonic VE0− case. Then, we give formal
conditions that will allow one to establish the pathwise derivative of the pa-
rameter specified by this formula. Finally, we describe how to modify our
estimator from the main text so that the validity of the confidence intervals
neither relies on P 0? {VE0−(W ) = θ0} = 0 nor on C7.
E.2.1 Partial bridging formula. We will use the notation from the main
text to express our partial bridging formula. We will define alternatives to θ0,
η0, β0, and φ0, which we will respectively denote by θ0, η0, β0, and φ0.
Define
θ0 , sup
{
θ ∈ R : ωw 7→1{w<θ},0 ≤ µ
}
,
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where sup ∅ = −∞ by convention. Let β
η
, w 7→ 1{w<θ0}+η 1{w=θ0}, and
define η0 to be the smallest element of the set argminη∈[0,1]
(
ω
β
η
,0 − µ
)2
. Let
β0 , β
η0
. One can show that, if E0?[λ0(W )] ≤ µ ≤ E0?[υ0(W )], then ωβ
0,0 = µ.
Our partial bridging parameter is given by
Φ(P0) , γ
β0,0
ωβ
0,0
, φ0.
The proof of the following lemma is nearly identical to the proof of Lemma 1
and so is omitted.
Lemma A.15. Suppose M, B1, B2, B3, and B4 hold. If µ = E0?[E
0,F
? [Y |A =
0,W ]], then Ψ(P 0,F? ) ≥ φ0.
E.2.2 First-order expansion of φ0. Our first-order expansion also re-
places C1 in the main text with two alternative assumptions, the first of which
is given below.
D1) E0?[λ0(W )] < µ < E
0
?[υ
0(W )] and either (i) P 0? {W = θ0} > 0 or (ii)
P 0? {W = θ0} = 0, w 7→ VE0−(w) is Lipschitz at θ0, and
0 < lim inf
t→0
P 0? {W < θ + t} − P 0? {W < θ}
t
.
Note that E0?[λ0(W )] < µ < E
0
?[υ
0(W )] implies that θ0 is finite.
We give a theorem presenting the gradients of our parameter. For brevity,
we only sketch the proof.
Theorem A.16. If B3 and B4 hold and either D1, C1’, or C1” holds, then
Φ is pathwise differentiable and, for each s ∈ S, the P 0s gradient is given by
∇Φ0s(os) =

∇Γβ
0,0
s (os)
ωβ
0,0
− VE0−(θ0)
∇Ωβ
0,0
s (os)
ωβ
0,0
, if E0?[λ0(W )] < µ < E
0
?[υ
0(W )],
∇Γβ
0,0
s (os)
ωβ
0,0
− γβ0,0∇Ω
β0,0
s (os)
[ωβ
0,0]2
, otherwise.
.
Sketch of Proof of Theorem A.16. The proof under C1’ or C1” is essentially
identical to that of Theorem 2 under the same conditions, we suppose D1 in
the remainder.
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We first outline the convergence result of β to β0. If (i), then we can
instead show that θ = θ0 for all  small enough and η = η0 + O(). If (ii),
then D1 yields that θ = θ0 + O(). In either case, θ0 is finite for all  small
enough so that ωβ
, = µ for all  small enough. Hence,
φ − φ0

= µ−1
γβ
, − γβ0,0

,
so it is enough to study the right-hand side multiplied by µ. We will use that
γβ
, − γβ0,0 =
{
γβ
0, − γβ0,0 − VE0−(θ0)[ωβ
0, − ωβ0,0]
}
+ VE0−(θ0)
[
ωβ
, − ωβ0,0
]
+
{
γβ
, − γβ0, − VE0−(θ0)[ωβ
, − ωβ0,]
}
A delta method argument shows that dividing the leading term by  and
taking the limit as  → 0 yields ∑s∈S P 0s hs[∇Γβ0,0s (os) + VE0−(θ0)∇Ωβ0,0s ]. As
we established earlier in this proof, ωβ
, = µ = ωβ
0,0 for all  small enough, so
that the second term above is zero for all  small enough . The remainder of
this proof aims to show that the final term is o(). We will use a constant c that
may vary line by line. We now study the final term above, whose numerator
bounds as∣∣∣γβ, − γβ0, − VE0−(θ0)[ωβ, − ωβ0,]∣∣∣
= (1 + c||)E0?
∣∣{υ(W )− λ(W )}{β(W )− β0(W )}{VE−(W )− VE0−(θ0)}∣∣
≤ (1 + c||)E0?
[|β(W )− β0(W )|{∣∣VE0−(W )− VE0−(θ0)∣∣+ c||}] .
Call the right-hand side T 1. If (i) holds, then the fact that θ
 = θ0 for all 
small enough shows that, for all such ,
T 1 ≤ c||(1 + c||)|η − η0|P 0? {W = θ0}.
As η − η0 = O(), the right-hand side must be o(). If, instead, (ii) holds,
then similar techniques to those used to control T 1 in Theorem A.3 show that
T 1 ≤ (1 + c||)E0?
[
1{0<|W−θ0|<|θ−θ0|}
{∣∣VE0−(W )− VE0−(θ0)∣∣+ c||}] .
By the fact that VE0− is Lipschitz at θ0 and the bound on |W − θ0| given in
the indicator, we have that
T 1 ≤ (1 + c||)
{
c
∣∣θ − θ0∣∣+ c||}P 0? {0 < |W − θ0| < |θ − θ0|} .
As θ− θ0 = O() and the probability statement is o(1), the right-hand side is
o().
54
E.2.3 Modification to our estimator. We now present the modification
to the estimator presented in the main text that allows us to replace the
condition that VE0−(W ), W ∼ P 0? , does not concentrate mass at a decision
boundary with the condition that W ∼ P 0? does not concentrate mass at a
decision boundary and the monotonicity condition M.
The first 5 steps of our estimation procedure are identical to that in the
main text, and the modification of the remaining steps is given below.
6. Let θ̂
n , sup{θ : ω̂w 7→1{w<θ},n ≤ µ}, where sup ∅ = −∞.
7. Let η̂n be any element of the set argminη∈[0,1]
(
ω̂βη ,n − µ)2, where βη ,
w 7→ 1{w<θ̂n}+η 1{w=θ̂n}.
8. Let β̂
n , βη̂n .
9. Estimate γβ̂
n
,0 with
γ̂β̂
n
,n , γβ̂
n
,n +
∑
s∈S
Qns∇Γ
β̂
n
,n
s
= n−1?
n?∑
i=1
URβ̂
n
,n(w?[i]) VE
n(w?[i]) +
S∑
s=1
Qns∇Γ
β̂
n
,n
s .
10. Estimate φ0 with φ̂
n , γ̂β̂
n
,n
ω̂β̂
n
,n
.
The conditions for the asymptotic linearity of this approach are similar to
those of Theorem 3, but weaker because they do not rely on the condition that
P 0? {VE0−(W ) = θ0} = 0 (nor any analogue thereof). To start, we consider why,
at least for W continuous, P 0? {VE0−(W ) = θ0} = 0 was essentially necessary
for it to be plausible that the procedure in the main text was asymptotically
linear. For asymptotic linearity to hold, the indicators that VEn−(w) < θ̂n
and VEn−(w) = θ̂n that appear in the empirical gradients must converge to a
fixed limit. The fact that VEn− is only an estimate of VE0− suggests that it is
not plausible that the indicators of the events VEn−(w) < θ̂n or VEn−(w) = θ̂n
converge to a fixed limit for any w for which VE0−(w) = θ0. Thus, if W is
continuous and P 0? {VE0−(W ) = θ0} > 0, then it is not plausible that these
indicators converge to any fixed limit.
Consider now the procedure above. The procedure above replaces the
indicators that VEn−(w) < θ̂n and VEn−(w) = θ̂n with indicators that w < θ̂
n
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and w = θ̂
n
: in particular, it is expected to be valid regardless of the value
of P 0? {W = θ0}. The conditions needed to ensure that these new indicators
converge to a fixed limit are weaker than those needed for the convergence
of VEn−(w) < θ̂n or VEn−(w) = θ̂n. If P 0? concentrates mass at θ0, then we
expect that θ̂
n
will equal θ0 with probability approaching one, so that clearly
the indicators that w < θ̂
n
and w = θ̂
n
are fixed with probability approaching
one. If, on the other hand, P 0? does not concentrate mass at θ
0, then indicators
that w < θ̂
n
and w = θ̂
n
will generally converge to a fixed limit if θ̂
n → θ0. For
some intuition on why θ̂
n → θ0 is to be expected, note that θ̂n is essentially an
empirical quantile for an (υ0−λ0)-weighted version of P 0? . We say “essentially”
because conditions can be given under which we can replace the estimated
weights υn−λn by the true weights υ0−λ0 at the expense of an OP (n−1/2min ) term.
Given this replacement, we can show that D1 yields that θ̂
n
= θ0 +OP (n
−1/2
min ).
Note that this is stronger than the slower than root-n rate of convergence of
θ̂n to θ0 in the nonmonotonic case given in Lemma A.14.
F Nested case-control simulation results
Figure 3 shows that our the coverage of our estimation scheme decreased under
the 1:1 nested case-control design, though also that this coverage improves
with sample size. At the Moderate and Tight settings, Figure 4 shows that
our estimate of the partially bridged lower bound has positive bias for the
nested case-control design, though that this bias reduces with sample size.
Figure 5 compares the Monte Carlo variance of the estimator that uses the
known censoring mechanism versus the estimator that estimates the censor-
ing mechanism. The two procedures appear to have similar variance in this
particular simulation setting.
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Figure 3: Comparison of the coverage of our lower confidence bound for φ0, i.e.
the lower bound on the vaccine efficacy, when there is and is not data missing
due to a nested case-control sampling design. Conducted at both smaller and
larger sample sizes, respectively with (n?, n1, n2) equal to (100, 2000, 2000)
and (200, 4000, 4000), and for different choices of `s and us, determining the
tightness of the unvaccinated risk bounds. Horizontal dashed lines drawn at
95% coverage, vertical dashed lines drawn at the true baseline risk value µ.
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Figure 4: Comparison of average estimates (solid lines) and lower confidence
bounds (dashed lines) for φ0, i.e. the lower bound on the vaccine efficacy,
when there is and is not data missing due to a nested case-control sampling
design. Conducted at both smaller and larger sample sizes, respectively with
(n?, n1, n2) equal to (100, 2000, 2000) and (200, 4000, 4000), and for different
choices of `s and us, determining the tightness of the unvaccinated risk bounds.
Black trend lines denote true (`s,us, µ)-specific lower bound.
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Figure 5: Comparison of estimator’s Monte Carlo variance in the presence
of two-phase sampling (standardized by Monte Carlo variance of estima-
tor that observed W for all individuals). Conducted at both smaller and
larger sample sizes, respectively with (n?, n1, n2) equal to (100, 2000, 2000)
and (200, 4000, 4000), and for different choices of `s and us, determining the
tightness of the unvaccinated risk bounds.
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